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Summary 
 
Aortic valve stenosis is the commonest valvular heart disease in western world. An 
incidence of aortic valve stenosis is increasing as ageing of population. In spite of 
several option for management of this disorder like observation, medical treatment, 
balloon valvuloplasty, surgical aortic valve replacement is consider as the gold 
standard. However, there are 2/3 of patients are consider as high risk for surgical 
treatment and refused by surgeon for open heart surgery. Therefore, with the ageing 
of global population, the lengthening in life-expectancy and the consequent growing 
need to treat elderly patients with severe AS, there is a wide population who would 
benefit from a less invasive way of replacing the aortic valve. Transcatheter aortic 
valve implantation (TAVI) allows the aortic valve to be implanted without a 
sternotomy, with beating heart and without the need for routine cardiopulmonary 
support. 
In the present series, we reported our prospective single centre experience about 
TAVI in a the Department of Cardiovascular Sciences, at the University of Verona, 
using both balloon expandable Edward-Sapien and self expanding Core-Valve 
devices, through trans-femoral, trans-apical and sub-clavian approaches. We report 
on early (30days) and long term follow up results, focusing on both clinical outcome 
and hemodynamic performance of the devices. We also investigated some peculiar 
fields of application, such as the treatment of severe aortic insufficiency in Heart 
Mate II patient, and speculated on the main potential procedural complications, such 
as the vascular complication and the periprosthesis leakage. 
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In present series we found that procedural success was high. Hemodynamic function 
of prosthesis was well maintained up to long term follow up. Moreover, neither 
patient needed emergency conversion to open heart surgery nor underwent aortic 
valve replacement on long term follow up. Non-cardiac mortality was higher than 
cardiac causes on both short term and long term follow up. Euroscore II is more 
predictor of operative mortality then logistic Euroscore. High EuroScore II and heart 
failure patients are predictor of long term mortality. Vascular complication was most 
common immediately after procedure. Proper patients screening and selection of 
proper approach is key to success. Recent improvements in the introducer and 
delivery system increase the procedural success and decrease complications. 
We strongly believe that, once some current limitations and concerns are overcome, 
this emerging technique will have a very fast and wide spread. However, it should 
not be forgotten that, in order to guarantee the extraordinary success of this new 
minimally invasive procedure, the heart team approach should remain a key-point. 
This will allow to select the best device and the most appropriate vascular access for 
each patient, as well as to guarantee the best technical result and the necessary 
post-procedural care.  
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1. Introduction 
 
1.1 Epidemiology and aetiology of Aortic valve stenosis 
Aortic stenosis (AS) is the most commonly acquired valvular heart disease in the 
Western world (2–7% of the population aged >65 years), mostly related to the 
significant increase in the average life span of the population [1]. Moreover, in the 
coming decades, there will be a tremendous aging of the population in developed 
countries with a unique increase of inhabitants older than 80 years [2]. Hence, AS 
will become more frequent and constitute a growing burden for public health.  
1.2 Pathophysiology of Aortic Stenosis 
The aortic valve stenosis is defined as an obstacle to the flow of blood through the 
aortic valve during left ventricular (LV) ejection. In AS there is a reduction in cusp 
motion and effective valve area: the stenosis is caused by deposits of calcium from 
the base to the distal tip of the cusps, without commissural fusion [3] as showed in 
Figure 1.  
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Figure 1 showed a macroscopic view of aortic valve: normal aortic valve (left side), severely 
calcified aortic valve (right side) 
The aetiology of aortic valve stenosis is varied with age of patient. The bicuspid 
aortic valve is most prevalent cause of aortic stenosis in young, however, 
degenerative aortic valve disease in elderly patients [4] as demonstrated in Figure 2.  
 
Figure 2 showing aetiology of aortic valve stenosis according to the age of patients 
Alterations in hemodynamic of aortic valve are established when the valve area is 
reduced by at least 50% [5]. Severity of aortic valve stenosis is classified according to 
aortic valve area; peak gradient; mean gradient and jet velocity measured by 
echocardiography (Table 1).  
Table 1- classification of aortic valve stenosis 
AS/echo Area (cm2) Mean gradient(mmHg) Jet Velocity (m/s) 
Mild 1.5 <25 <3 
Moderate 1-1.5 25-40 3-4 
Severe <1 >40 >4 
15 
 
 
The pressure overload, established with AS, is initially compensated by the 
development of myocardial hypertrophy without dilatation of the left ventricular 
chamber (concentric hypertrophy) that is able to maintain for many years normal 
systolic function. However, the increases in systolic blood pressure, ventricular mass 
and ejection time lead to increased consumption of oxygen by the myocardium. The 
increase in oxygen consumption and its contributing to decreased myocardial 
ischemia cause further deterioration of LV function [6].  
In more advanced disease, the disappearance of effective compensatory 
mechanisms is associated with an imbalance between pump function and LV 
afterload (afterload mismatch). At this stage, the ventricular chamber dilates, the 
ejection fraction (EF) is reduced and both the ventricular filling pressure and 
pulmonary pressure increase. This stage usually coincides with the occurrence of 
severe stenosis and the onset of symptoms. Usually, the symptoms in patients with 
AS appear around the 6th decade of life after a long latency period, characterized by 
progressive thickening and calcification of the aortic valve or progressive myocardial 
dysfunction, or both as showed in Figure 3 [7]. 
 1.3 Clinical manifestation of aortic stenosis 
In the natural history of adults with AS, a long latent period exists during which there 
is gradually increasing obstruction while the patient remains asymptomatic [8]. The 
cardinal manifestations of acquired AS, which commence most commonly in the fifth 
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or sixth decades of life, are angina pectoris, syncope, exertional dyspnea, and 
ultimately heart failure [9]. 
Angina occurs in approximately two-thirds of patients with critical AS (about half of 
whom have associated significant coronary artery obstruction). In patients without 
coronary artery disease, angina results from the combination of the increased 
oxygen needs of the hypertrophied myocardium and the reduction of oxygen 
delivery secondary to the excessive compression of intramural coronary vessels [10]. 
In patients with coronary artery disease, angina is caused by a combination of the 
epicardial coronary artery obstruction and the earlier-described oxygen imbalance 
characteristic of AS. 
Syncope is most commonly due to the reduced cerebral perfusion that occurs during 
exertion when arterial pressure declines consequent to systemic vasodilation in the 
presence of a fixed cardiac output. Syncope has also been attributed to malfunction 
of the baroreceptor mechanism in severe AS, as well as to a vasodepressor response 
to a greatly elevated LV systolic pressure during exercise. Premonitory symptoms of 
syncope are common. 
Exertional dyspnea: orthopnea, paroxysmal nocturnal dyspnea, and pulmonary 
edema reflect varying degrees of pulmonary venous hypertension. 
Sudden death: In asymptomatic AS and in the absence of coronary artery disease the 
incidence of sudden death is low and not significantly different from that of the 
general population. However, in symptomatic patients, sudden death is reported 
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between 13-34%, in relation to ventricular tachyarrhythmias, or conduction 
disorders (CD) or abnormal Bezold Jarisch reflex (hypotension, bradycardia). 
Gastrointestinal bleeding, either idiopathic or due to angiodysplasia (most commonly 
of the right colon) or other vascular malformations, occurs more often in patients 
with calcific AS than in persons without this condition; it may cease after aortic valve 
replacement (AVR) [11]. 
1.4 Natural history of aortic stenosis 
The natural history of AS in the adult consists of a prolonged latent period in which 
morbidity and mortality are very low. The rate of progression of the stenotic lesion 
has been estimated in a variety of hemodynamic studies performed largely in 
patients with moderate AS. Cardiac catheterization and Doppler echocardiographic 
studies indicate that some patients exhibit a decrease in valve area of 0.1 to 0.3 cm2 
per year; the average rate of change is approximately 0.12 cm2 per year [12]. The 
systolic pressure gradient across the valve may increase by as much as 10 to 15 mm 
Hg per year. However, more than half of the reported patients showed little or no 
progression over a 3 to 9-year period and it is not possible to predict the rate of 
progression in an individual patient. 
Eventually, symptoms of angina, syncope, or heart failure develop after a long latent 
period, and the outlook changes dramatically. After onset of symptoms, average 
survival is <2 to 3 years [13]. Thus, the development of symptoms identifies a critical 
point in the natural history of AS and patients with severe AS require careful 
monitoring in order to identify the more appropriate timing for surgery. In fact, in 
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patients in whom the obstruction remains unrelieved, the prognosis is poor once 
these symptoms are manifested. Survival curves show that the interval from the 
onset of symptoms to the time of death is approximately 2 years in patients with 
heart failure, 3 years in those with syncope, and 5 years in those with angina (Figure 
3). 
1.5 Management of aortic stenosis 
The course of symptomatic severe AS under medical treatment has high mortality 
rates. After the onset of heart failure, syncope and angina a median survival is only 
11, 27 and 45 months, respectively, as shown in Figure 3 [14]. The balloon aortic 
valvuloplasty (BAV) can only be considered as a palliative treatment method for 
patients with a good quality of life (QoL) who are not eligible for surgical aortic valve 
replacement (sAVR). However, it has high risk of restenosis [15-18].  
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Figure 3 . Symptoms in patients with aortic stenosis begin around the 6th decade of life, after 
a long latency period, and are characterized by progressive thickening and calcification of the 
aortic valve or progressive myocardial dysfunction, or both. Without aortic valve 
replacement or transcatheter aortic valve implantation the prognosis of patients with aortic 
stenosis after the onset of severe symtoms is extremely poor. (Branwald E.6) 
 
Up to date the surgical aortic valve replacement (sAVR) is considered as the gold-
standard treatment for patients with severe symptomatic AS. This is typically a well-
tolerated and durable intervention. Clinical outcomes after AVR have been quite 
good, with an overall operative mortality rate for isolated AVR of 4% [19]. Without 
surgery, the prognosis is extremely poor, with a 3-year survival rate less than 30% 
[4]. However, the operative mortality rate for AVR in patients >80 years of age is as 
great as 8% to 15% [20-26]. 
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2. Criteria for aortic valve replacement in aortic stenosis 
 
2.1 For symptomatic aortic stenosis 
In patients in whom symptomatic severe AS is not treated, the prognosis is poor. For 
this reason, the ACC/AHA guidelines [7] recommend valve replacement in patients 
with severe symptomatic AS. According to the latest update of the ACC/AHA 
guidelines 2008 the indications for AVR are as follows. 
Table 2 Class I  
Aortic Valve Replacement Level of 
evidence 
Symptomatic patients with severe AS B 
Patients with severe AS undergoing coronary artery bypass graft surgery (CABG) C 
Patients with severe AS undergoing surgery on the aorta or other heart valves C 
Patients with severe AS and LV systolic dysfunction (EF <0.50) C 
 
There are two important considerations in elderly patients with AS: the absence of 
symptoms despite severe AS, and patients with low-flow/low-gradient AS. 
2.2 For asymptomatic Patients with Severe AS 
Asymptomatic patients with AS have outcomes similar to age-matched normal 
adults. However, disease progression with symptom onset is common. There is a 
high probability that these patients will need to undergo surgery within the 5 years 
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after symptom onset. The assessment should only be done by a high-quality 
cardiology group and the procedure by a high-quality surgical group where the risk is 
1% or less [7].  
Table 3 Class IIb 
Aortic Valve Replacement Level of 
evidence 
Asymptomatic patients with severe AS and abnormal response to exercise C 
Adults with severe asymptomatic AS if there is a high likelihood of rapid 
progression or if surgery might be delayed at the time of symptom onset 
C 
Patients undergoing CABG who have mild AS when there is evidence, such as 
moderate to severe valve calcification, that progression may be rapid 
C 
Asymptomatic patients with extremely severe AS (aortic valve area <0.6 cm2, 
mean gradient> 60 mmHg and jet velocity >5.0 m/s) when the patient’s expected 
operative mortality is 1.0% or less 
C 
 
In asymptomatic patients, symptoms such as heavy calcification or very severe AS 
are important. A recent study by Rosenhek et al pointed out that patients with a 
valve peak velocity greater than 4 m/s have a high likelihood of requiring surgery 
over the course of the next 3–4 years [27]. If the velocity is greater than 4.5 or 
greater than 5, the attrition rate is even more important, so a very severe degree of 
AS may be enough to consider surgery as long as it is performed by a high-quality 
surgical group. 
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2.3 What is different in the European guidelines?  
However, the European guidelines [1] recommend surgery in asymptomatic patients 
with AS as follows. 
Class I Asymptomatic patients with severe AS and abnormal exercise test showing 
symptoms on exercise (level of evidence: C). 
Class IIa Asymptomatic patients with severe AS and abnormal exercise test showing 
a fall in blood pressure below baseline (level of evidence: C). 
Flow chart 1 demonstrated a treatment algorithm in patients with severe AS.  
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Figure 3 Management strategies for patients with severe aortic stenosis. (AVA-aortic valvular 
area; BP-blood pressure; CABG-coronary artery bypass graft surgery; echo-
echocardiography; LV-left ventricular; Vmax-maximal velocity across the aortic valve by 
Doppler echocardiography) 
 
A study by Pai et al [28] reveals how complex asymptomatic patients with AS can be. 
Patients with no symptoms can still have a high mortality rate, especially the older 
group. In addition, it is can sometimes be difficult to establish the presence of 
symptoms, for a variety of reasons. A study by Otto et al confirmed the findings of 
previous studies showing importance of aortic valve velocity, found that patients 
with a peak velocity >4 m/s, which is how severe AS is being defined, either 
underwent surgery or had a bad outcome over the course of the subsequent 5 years 
[12]. 
2.4 For patients with Low-Flow/Low-Gradient AS 
Patients with severe AS (<1 cm2) and low cardiac output often present with a 
relatively low transvalvular pressure gradient (ie, mean gradient <30 mmHg). Such 
patients can be difficult to distinguish from those with low cardiac output and only 
mild to moderate AS. In the former (true, anatomically severe AS), the stenotic lesion 
contributes to an elevated afterload, decreased EF, and low stroke volume (SV) [7]. 
In the latter, primary contractile dysfunction is responsible for the decreased EF and 
low SV. The problem is further complicated by a reduction in the valvular opening 
forces that contributes to limited valve mobility and apparent stenosis. Therefore, it 
may be useful to determine the transvalvular pressure gradient and to calculate 
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valvular area during a baseline state and again during exercise or low-dose 
pharmacological (ie, dobutamine infusion) stress, with the goal of determining 
whether the stenosis is severe or only moderate. Thus, if a dobutamine infusion 
produces an increment in SV and an increase in valve area greater than 0.2 cm2 and 
little change in gradient, it is likely that the baseline evaluation overestimated the 
severity of the stenosis. In contrast, patients with true severe AS will have a fixed 
valvular area with an increase in SV and an increase in gradient during dobutamine 
infusion. These patients are likely to respond favorably to surgery and perhaps to 
TAVI. 
2.5 Why we need new technique for management of aortic stenosis 
Although surgical AVR is regarded to be the mainstay for improved survival and 
symptom relief, not all patients, especially the elderly, are able to profit from this 
technique [29,30]. The European Heart Survey of patients with valvular heart disease 
suggests that up to 33% of subjects over the age of 75 are not considered for surgical 
AVR because of age and comorbidities [31]. Moreover, Vardarajan P et al 
demonstrated that the mortality for untreated symptomatic severe AS is up to 50– 
60% at 2 years in high-risk patients, and among such patients those who ultimately 
undergo surgical valve replacement, a proportion is at high risk of 
morbidity/mortality from the procedure(Figure 2) [30].  
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Figure 4 demonstrated that33% of all patients aged >75 years with severe aortic stenosis (AS) are 
declined for surgery. The mortality for untreated symptomatic severe AS is up to 50–60% at 2 years in 
high-risk patients (red line). Of these patients, among those who ultimately undergo surgical valve 
replacement, a proportion is at high risk of morbidity/mortality from the procedure. AVR, aortic valve 
replacement. (Modified from Varadarajan P et al.Speccarotella 20122,3) 
 
However, recently introduced transcatheter aortic valve implantation (TAVI) is a 
new, innovative invasive procedure that promises effective treatment for high-risk 
patients which are not suitable for surgical AVR.  
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3. Trans-catheter Aortic Valve Implantation (TAVI) 
 
3.1 Birth of concept “TAVI”  
Actually, the concept of transcatheter heart valve implantation was not new. In the 
1970s, several projects aimed at treating aortic regurgitation [32-34]. remained 
experimental. In 1989, Henning-Rud Andersen first implanted an original model of a 
balloon-expandable catheter-mounted stented valve within the aorta of pigs, using a 
handmade mesh containing a porcine valve. The results, published in 1992 [35], 
were not followed by human application. Other experimental concepts emerged 
thereafter [36-38]. In 2000, Philip Bonhoeffer developed a stented valve made of a 
bovine jugular vein conduit inserted in a platinum-iridium stent, which was 
implanted in the pulmonary artery of lambs [39]. Followed by this animal model he 
performed the first human implantation of same device in a right ventricle to 
pulmonary artery conduit in 2000 [40]. Success of this followed by intensive 
technical development in this indication.  
3.2. Tribute to Prof. Alian Cribier 
The idea of percutaneous treatment of aortic stenosis was first put into clinical 
practice in 1985, when Cribier performed an aortic balloon valvuloplasty for non-
operable severe calcified aortic stenosis [41]. Concept of having stented aortic valve 
was put forward by him. After lots of heard effort, Edward group accepted proposal 
to produce device. In the 2002, “golden year” of TAVI, the first in human successful 
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percutaneous aortic valve implantation performed by Alain Cribier, via trans-venous 
antigrade approach, with septal puncture [42]. This was a very complex technique 
with high incidence of complication. At same time John Webb performed retrograde 
implantation aortic prosthesis via femoral artery access [43]. Initial series has several 
complications mainly vascular which stimulate need for improvement in TAVI 
technique, prosthesis and delivery system. Up to date, more than 50,000 patients 
have been treated with this novel technique worldwide.  
There are several prosthesis devices. However, in Europe, the Edwards SAPIEN valve 
(Edwards Lifesciences, Irvine, CA) and the CoreValve ReValving System (Medtronic, 
Minneapolis, MN) are used most frequently and both devices have received the CE 
(European Conformity) mark, based on the clinical trials. 
3.3 Anatomy of aortic-root for TAVI 
The aortic root is the direct continuation of the left ventricular outflow tract (LVOT). 
Its components are the sinuses of Valsalva, the fibrous interleaflet triangles, and the 
valvular leaflets themselves. When defined literally, an “annulus” is no more than a 
little ring [44].  
Aortic Valvar Leaflets-The normal aortic valve is tricuspid, and proper functioning of 
the valve depends on the proper relationship between the leaflets within the aortic 
root. In the majority of cases, the orifices of the coronary arteries arise within the 2 
anterior sinuses of Valsalva, usually positioned just below the sinotubular junction 
[43]. Knowledge of the location of the coronary arteries, of course, is essential for 
appropriate percutaneous replacement of the aortic valve. The combination of a 
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relatively low-lying coronary artery ostium and a large native aortic valvular leaflet 
can therefore obstruct the flow into the coronary arteries during valvular 
deployment [42-44].  The presence of a significant subaortic bulge or a 
hypertrophied septum has been considered a relative contraindication to 
implantation, mainly for the CoreValve aortic prosthesis. The atrioventricular node is 
located just inferior to the apex of the triangle adjacent to the membranous septum, 
and therefore the atrioventricular node is in fact in close proximity to the subaortic 
region and the membranous septum of the LVOT. 
3.4 Role of Heart Team 
First of all, it should be stressed that today and in the future, the TAVI Heart Team 
approach is and will remain, essential for the management of patients with severe 
aortic stenosis. [44, 45] This will apply at each step of the procedure: patient 
selection, performance of the procedure, post-procedural care and evaluation of the 
results. The Heart Team is comprised of clinical cardiologists, interventionists, 
surgeons, anaesthetists and imaging specialists, all with expertise in the treatment of 
valve disease. Heart team approach is the key to success of this new technique. 
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4. Screening for TAVI 
 
Patient selection plays a crucial role in the success of transcatheter aortic valve 
implantation (TAVI). It requires meticulous attention to the smallest of details and 
needs to be performed in a systematic manner for every patient. In addition to 
patient risk evaluation, anatomical selection criteria need to be considered. 
Multimodality imaging, using a combination of angiography, echocardiography and 
multislice computed tomography (MSCT), is necessary to determine the anatomical 
suitability for the procedure. In particular, assessment of the peripheral vasculature 
and aortic valvar complex will allow selection of the access route and prosthesis type 
and size, respectively [46].  
Following variable to be assessed during assessment of TAVI candidate- 
4.1 Patients risk evaluation 
The logistic EuroSCORE I and the STS (Society of Thoracic Surgeons) are mostly 
commonly used as Predicted Risk of Mortality score. These scores have guided 
enrolment of ‘‘high surgical risk’’ patients into TAVI trials. Because low-to-
intermediate surgical risk patients characterized the development of these risk 
models, their reliability when applied to high or prohibitive surgical risk patients has 
been rightfully questioned. Furthermore, models may not take into account 
important comorbidities (e.g. porcelain aorta, chest wall radiation, liver cirrhosis, 
pulmonary hypertension) and frailty variables that may impact clinical outcomes. 
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The newly updated logistic EuroSCORE II and STS score, however, are expected to 
incorporate frailty variables. In high surgical risk patients, the logistic EuroSCORE I 
tend to overestimate the observed mortality risk by a factor of 2 to 3; the new 
logistic EuroSCORE II appears to provide significantly lower mortality estimates than 
the logistic EuroSCORE I. The STS score has been found to be more reliable than the 
logistic EuroSCORE I or the Ambler Risk Score for the prediction of operative and 
long-term mortality in high-risk patients undergoing surgical aortic valve 
replacement. Risk scores should guide but not dictate clinical decision-making [47]. 
4.2 Anatomical patient selection  
The most important aspect of anatomical screening involves assessment of the 
arterial vasculature and aortic valvar complex (left ventricular outflow tract, aortic 
annulus, sinus of Valsalva, sinutubular junction and ascending aorta.  
4.2.1 Access selection: This information will guide physicians to select the most 
appropriate access route (i.e. transfemoral, subclavian, apical or direct aortic) and 
transcatheter valve size. Furthermore, it will alert physicians to potential 
complications that may arise during the procedure. Following imaging technique 
used: 
1. Peripheral contrast angiography- practical, low cost, less contrast and 
radiation exposure. 
2. MSCT- greater appreciation of vessel size, tortuosity and calcification. 
Acceptable minimal ilio-femoral diameters for implantation of the 23, 26 and 
29 mm Edwards SAPIEN XT prostheses are 6.0, 6.5 and 7.0 mm, respectively. 
Although in case of self-expandable Medtronic Core Valve prosthesis the 
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acceptable minimal iliofemoral diameter for implantation of the 26, 29 and 
31 mm is 6.0 mm.  
Alternative routes to the transfemoral include the sub-clavian artery, apex of heart, 
trans-aortic, brachial and recently introduced axillary artery approach [48]. 
4.2.2 Measurement of aortic valve annulus- The aortic valve annulus diameter can 
be measured using various imaging modalities. These include transthoracic 
echocardiography (TTE), transesophageal echocardiography (TEE), MSCT, contrast 
aortography and magnetic resonance imaging [49]. 
Every patient must be screened thoroughly using proper investigation tool before 
performing TAVI. Rodés-Cabau in his recent review gives focus on pre-TAVI screening 
protocol, as showed in flowchart 2. 
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Flow chart 2 for screening in TAVI candidate 
 
Patients considered at very high risk or nonsurgical candidates 
 
Evaluation by a TAVI multidisciplinary team 
(interventional cardiologists and cardiac surgeons) 
 
Medical Treatment 
 
 
Coronary angiography 
Transthoracic/ transesophageal echocardiogram 
CT 
CT angiography and/ or iliofemoral angiography 
 
Iliofemoral axis > 6mm (Edwards SAPIEN XT  20 mm or CoreValve 26 mm, 29mm, 31mm) 
Iliofemoral axis > 6.5 mm (Edwards SAPIEN XT 26mm) 
Iliofemoral axis > 7mm (Edwards SAPIEN XT 29 mm) 
Absence of significant peripheral vascular disease 
Absence of severe iliofemoral calcification 
                         YES                                                                       NO 
Transfemoral approach using the 
Edwards SAPIEN XT or CoreValve 
systems 
 
Subclavian axillary approach using the CoreValve 
system with axilo-subclavian axis > 6mm and/ or > 
7mm with patent LIMA graft 
 
Transaortic approach using the Edwards SAPIEN 
XT or CoreValve systems 
 
Surgical aortic valve 
replacement 
Patients eligible for TAVI 
Transapical approach using the Edwards SAPIEN 
XT system 
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5. TAVI Devices 
 
5.1 Which are the most commonly used TAVI device?  
There are currently two TAVI devices in widespread use for the treatment of AS in 
Europe with the CE mark (Tables 4). The current generation Edwards SAPIEN XT 
valve (Edwards Lifesciences, Irvine, CA) is constructed on balloon expandable cobalt 
chromium frame to which are sewn bovine pericardial leaflets and a fabric sealing 
cuff (Figure  5a & 5b). The CoreValve device (Medtronic, Irvine, CA) consists of a self-
expanding nitinol frame to which are sewn porcine pericardial leaflets and a porcine 
pericardial sealing cuff (Figure 5c). Both valves are available with delivery catheters 
compatible with arterial sheaths with inner diameters of around 18Fr (Figure 6). The 
SAPIEN XT valve is also available with a delivery catheter designed to facilitate 
transapical implantation [50-52]. 
 
5.2 Comparison of Edward SAPIEN XT and Medronic CoreValve Prosthesis 
Edward SAPIEN XT and Medtronic CoreValve prosthesis are most frequently used in 
clinical practice, so necessary to understand their features, which helps in proper 
prosthesis selection. Comparisons of both devices are showed in table 4.  
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Table 4 Comparison of the Edwards SAPIEN XT and Medronic CoreValve Prostheses 
Characteristics Edwards SAPIEN XT Medronic CoreValve 
Frame Cobalt chromium Nitinol 
Leaflets Bovine pericardial Porcine pericardial 
Seal Synthetic Porcine pericardial 
Expansion Balloon expandable Self-expandable 
Repositionable No Yes 
Retrievable No Yes 
Annular/valvular fixation Yes Yes 
Ascending aorta fixation No Yes 
Manufacturers diameter 23,26 mm 26, 29 mm 
Treatable annulus diameter 18-25 mm 20-27 mm 
Length 15-17 mm 53-55 mm  
Sheath internal diameter 18F, 19F 18F 
Sheath external diameter 7 mm 7 mm 
Minimal arterial diameter 6 mm 6 mm 
Suitable for   
Aortic stenosis Yes Yes 
Aortic regurgitation If calcified stenosis 
present 
If size appropriate 
Dilated ascending aorta Yes No 
Pulmonary position Yes No 
Valve-in-Valve All 4 valve positions Aortic only 
Transapical access Yes No 
Transaxillary access Yes, limited experience Yes 
Transaortic access Yes Yes 
Largest published follow-up >6 yrs >4 yrs 
Pacemaker requirement 3%-8% 14%-40% 
CE mark approval Yes (2007) Yes (2007) 
FDA approval Sapien transfemoral only No 
Randomized trials results PARTNER A and B Results anticipated 2013 
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*SAPIEN XT 20, 29 mm (Edwards Lifesciences, Irvine, California); and CoreValve 
31(Medtronic, Minneapollis, Minnesota) device are available in some countries. 
 
 
Figure 5 Currently widely available Transcatheter Valves 
 
 
 
 
 
A) The Edwards SAPIEN THV balloon-expandable valve (Edwards Lifesciences, Irvine, 
California) incorporates a stainless steel frame, bovine pericardial leaflets, x and a fabric 
sealing cuff. (B) The SAPIEN XT THV (Edwards Lifesciences) utilizes a cobalt chromium alloy 
frame and is compatible with lower profile delivery catheters.(C) The Medtronic CoreValve 
(Medtronic, Minneapolis, Minnesota) incorporates a self-expandable frame, porcine 
pericardial leaflets, and a pericardial seal. 
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Figure 6 Valve delivery system 
 
 
  
(A, top) The RetroFlex 1 delivery system for the Edwards SAPIEN THV (Edwards Lifesciences, 
Irvine, California) as used in the PARTNER 1 (Placement of AoRTic TraNscathetER Valve 1) 
trials (8 mm diameter). (A, Middle) The RetroFlex 3 system (Edwards Lifesciences). (A, 
Bottom) The NovaFlex/SAPIEN XT system (6 mm diameter; Edwards Lifesciences). (B) The 
Accutrak delivery system with the Medtronic CoreValve (6 mm diameter, also with a tapered 
nosecone; Medtronic, Minneapolis, Minnesota). The prosthesis is enclosed within an outer 
sheath. 
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5.3 New generation prosthesis devices 
Several newer valves are currently in early clinical trials; including the Engager 
(Medtronic Inc.), Lotus (Boston Scientific Inc.,), Direct Flow (Direct Flow Medical 
Inc.,) JenaClip (JenaValve Inc.,) and the Accurate (Symetis Inc.,) valves as showed in 
figure 7. These newer valves offer the potential of lower diameter and less traumatic 
catheters, features which facilitate accurate positioning, improve paravalvular 
sealing or allow retrieval and repositioning [50-54]. 
 
Figure 7 Valve undergoing early evaluation 
 
 
 
 (A) Lotus (Boston Scientific Inc., Natick, Massachusetts), (B) Direct Flow (Direct Flow Medical 
Inc., Santa Rosa, California), (C) HLT (Bracco Inc., Princeton, New Jersey), (D) Portico (St. Jude 
Medical Inc., St. Paul, Minnesota), (E) Engager (Medtronic Inc., Minneapolis Minnesota), (F) 
JenaClip (JenaValve Inc., Munich, Germany), (G) Acurate valve (Symetis Inc., Ecublens, 
Switzerland), and (H) Inovare (Braile Biomedica Inc., São José do Rio Preto, Brazil) valves. 
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5.4 Advantages of New generation device over first generation devices 
Although these newer valves offer many desirable features, there are 
concerns with respect to radial strength, symmetric expansion, and late fracture with 
nitinol. Experience with newer leaflet technology is limited. Repositionable valves 
may be associated with aortic injury, atheroembolism, or reduced durability. 
Whether clinical outcomes will be equivalent or superior to currently available THVs 
will need to be evaluated [50-54]. 
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6. Endovascular Access 
 
6.1 Transfemoral artery 
The femoral artery has been the most popular access site. Although originally 
requiring a surgical cutdown most experienced groups now utilize a percutaneous 
puncture and suture pre-closure technique avoiding the need for open surgical 
access. Current consensus, with some exceptions, strongly favours transfemoral 
arterial access as the preferred, default approach for TAVR (Figure 8). 
Current transcatheter valve systems utilize vascular access sheaths, which are 
typically described in terms of their inner diameter in French size (3 x internal 
diameter in millimeters). Sheath external diameters are slightly larger. The only 
approved device in the United States (SAPIEN valve) requires a 22-F or 24-F sheath 
with outer diameters of just over 8 or 9 mm, respectively. However, current 
generation systems generally utilized outside the United States utilize smaller 
sheaths (< 18-F with outer diameters of 7 mm). A relatively compliant non diseased 
artery can generally accommodate a sheath slightly larger than its internal diameter. 
In the absence of severe calcification, tortuosity, or atheroma an arterial diameter <6 
mm might be adequate for an 18-F system, while an arterial diameter of >8 mm 
might be required for a 24-F system. Assessing this minimal arterial diameter is 
fundamental to patient selection. However, many patients have small or diseased 
femoral arteries. On occasion an open surgical retroperitoneal approach is utilized to 
gain access to the larger iliac artery in patients with femoral disease. Recently, 
transaxillary (sometimes referred to as subclavian) access has gained popularity as 
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an alternative to femoral access, although a surgical cutdown is generally utilized 
[51,53,55,56].  
 
6.2 Trans-apical approach 
A transapical approach, with direct access to the left ventricle through an intercostal 
thoracotomy, has several potential advantages: a low risk of peripheral vascular 
injury, a direct pathway to the aortic valve, and easier antegrade crossing of the 
diseased aortic valve. Concerns relate to direct myocardial injury, bleeding, mitral 
injury, hemodynamic instability, and post-operative respiratory compromise and 
thoracotomy pain. The transapical procedure is generally associated with the 
Edwards SAPIEN valve, although a number of newer valves (e.g., JenaClip, Engager, 
Portico, Acurate) have been developed for this application [52]. Figure 8 showed 
most commonly used TAVI access. 
6.3 Newer approaches for aortic valve implantation 
Most recently, a transaortic approach with direct access to the ascending aorta has 
been advocated. Although requiring a mini-thoracotomy and aortotomy, potential 
advantages over the transapical approach include a reduced risk of myocardial injury 
and bleeding and an access route more familiar to cardiac surgeons [52]. Moreover, 
in coming future, as new innovations are coming with prosthesis and delivery 
system, we are expecting even trans-brachial, trans-axillary approach. 
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Figure 8 showing different approaches for TAVI procedure 
 
 
 
 
 
a) The transfemoral approach. The delivery catheter for implantation of the valve prosthesis 
is advanced through the right or left femoral arteries. b) The transapical approach. After left 
lateral minithoracotomy (usually between the fifth and sixth intercostal spaces), the delivery 
catheter for implantation of the valve prosthesis is advanced through the left ventricular 
apex. c) The transaortic approach. After right or mid ministernotomy, the delivery catheter 
for implantation of the valve prosthesis is advanced directly through the ascending aorta. d) 
The subclavian approach. The delivery catheter for implantation of the valve prosthesis is 
advanced through the subclavian artery (usually the left vessel). e) The transaxillary 
approach. The delivery catheter for implantation of the valve prosthesis is advanced through 
the axillary artery (usually the left vessel). 
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7. Valve Implantation 
 
 
7.1 Basic of valve implantation 
Balloon aortic valvuloplasty is systematically performed before valve implantation 
for both types of prosthetic valves currently used in TAVI, although Grube et al. have 
suggested direct implantation of the CoreValve system with no prior balloon 
valvuloplasty [51-53]. The Edwards valve is positioned using fluoroscopy, 
angiography, and transesophageal echocardiography, and valve expansion is 
achieved by balloon inflation under rapid pacing (180–220 bpm) to minimize cardiac 
output and avoid valve embolization during valve implantation (Figure 9a,b). 
CoreValve positioning is usually performed by fluoroscopy and angiography, and the 
valve is deployed without rapid pacing, by retracting the outer sheath of the delivery 
catheter (Figure 9c–e). 
 
 
 
 
 
 
 
 
 
43 
 
 
Figure 9 Valve implantation of balloon-expandable and self-expandable 
transcatheter valve 
 
 
 
a) Deployment of a balloon-expandable Edwards SAPIEN XT® (Edwards Lifesciences 
Corporation, Irvine, CA, USA) valve. The white arrow indicates the balloon during maximal 
expansion. b) Fluoroscopic image of an Edwards SAPIEN XT® valve (white arrow) after valve 
implantation. c,d) Deployment of a self-expandable CoreValve® (Medtronic CV Luxembourg 
S.a.r.l., Luxembourg) system. The white arrows indicate the outer sheath that is being 
retracted to allow the expansion of the valve. e) Fluoroscopic image of a third-generation 
CoreValve® system (white arrow) after valve implantation.  
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8. Scopes of thesis 
 
 
8.1 General assessment: 
1) To analyze safety and feasibility and 30 days outcome of TAVI procedure in a 
single centre series, using both Self expandable and balloon expandable devices. 
2) To analyze safety and feasibility and long term outcome of TAVI procedure in a 
single centre series, using both SE and balloon expandable devices. 
3) To analyze the durability over long term, by analyzing echocardiographic variables 
over time, using both SE and balloon expandable devices. 
4) To evaluate incidence, predictor and prognostic impact of acute kidney injury after 
TAVI. 
 
8.2 Special settings: 
5) To explore safety and feasibility of particular indications to TAVI, the treatment of 
severe aortic regurgitation in Heart Mate-II and bioprosthesis dysfunction by valve-
in-valve technique. 
6) To evaluate feasibility and safety of using “Limb-saving” contra-lateral 
implantation of a protection guide-wire in femoral access during TAVI. 
7) To evaluate feasibility and safety of trans-femoral TAVI in patient with aorto-iliac 
endoprosthesis and severely tortuous and atherosclerotic accesses-“Railing tract” 
technique. 
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8)  To evaluate the safety and feasibility of Core-Valve insertion without introducer 
sheath. 
9) To evaluate the safety and feasibility of the Subclavian approach in the TAVI 
8.3 Special cases 
10) How to manage patient accidental finding of left atrial thrombus in TAVI suite? 
Whether to quite the play or we have some option? 
11) How to overcome coronary occlusion found during balloon valvuloplasty: 
Challenges from the coronary arteries take off. Is it safe to put protection guide wire 
in high risk coronary? Is there possibility for introduction of angioplasty catheter on 
wire? 
12) To evaluate the feasibility and safety of TAVI without contrast medium, in severe 
renal failure. Is an expert transesophageal echocardiography is alternative? 
13) Step by step approach for a case of severe multi-level vascular disease waiting 
for TAVI- complex TAVI candidate. 
14) Safety and feasibility of TAVI in the patient of AVS with associated severe mitral 
regurgitation, coronary artery disease, and heart failure. 
8.4 Complications and their management: 
15) Challenges from the femoral vascular access 
16) “Tunnelling” of femoral arteries 
17) Sessile thrombus in aortic root after transapical aortic valve implantation. 
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9. Methodology 
 
 
9.1 Study population 
We prospectively enrolled all patients of severe symptomatic aortic valve stenosis 
with high risk for conventional valve surgery who are planned to trans-apical and 
trans-femoral aortic valve implantation between February 2010 and February 2013. 
An inclusion and exclusion criteria are as follow: 
 
9.1.1 Inclusion criteria 
1. Age >75 years  
2. Severe aortic stenosis from degenerative origin  
                   Symptomatic  
                   Valve area < 0.7 cm2 ( 1 cm2)*  
                   Aortic valve gradient- > 40 mmHg*  
3. Surgical mortality predicted by the logistic   
                   EuroSCORE >20% for age >75year 
                   EuroSCORE- 10-20% for age >85 years 
4. Alternative criteria  
                   Porcelain aorta  
                   Radiation of the sternum or chest deformities  
                   Precluding an open chest surgery  
                   Severe chronic obstructive pulmonary disease  
47 
 
                   Patients referred for surgery and rejected by the surgeon  
5. Adequate diameters  
                   Aortic annulus >18 mm and  ≤ 25 mm.  
                   Ilio-femoral axes >8 mm or 9mm.  
 
9.1.2 Exclusion criteria 
1. Left main stenosis > 70%, as assessed by coronary angiogram;  
2. Aortic annulus diameter<17 mm or >25 mm, as measured from the 
echocardiographic parasternal long axis view at the level of the leaflet 
attachment. 
3. Ilio-femoral disease or diameters <7 or 8mm, according to the diameter of 
the sheath (22 or 24F), as obtained by conventional angiography and 
computed tomography. 
4. Any condition that made the quality or duration of life unlikely, despite AVR. 
5. Hypersensitivity or contraindication to any study medication. 
6. Sepsis or active endocarditis 
7. Bleeding diathesis; or coagulopathy 
8. Patients with significant mitral valve regurgitation (3+/4+) 
9. Patients with clear bicuspid aortic valve, because of the presumed risk of 
poor seating or paravalvular regurgitation due to severe distortion of the 
native valve leaflets 
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9.1.3 Criteria for Transapical TAVI- 
1. Severe calcification and/ or tortuosity of iliac- femoral arteries with minimal 
internal diameter less than 6-8mm. 
2. Aortic aneurism with thrombus 
3. Chronic aortic dissection 
4. Co-arctation of aorta 
5. Previous aorto-femoral bypass 
6. Severe aortic angulations 
7. Severe atherosclerosis of ascending, descending aorta and aortic arch 
 
9.2 TAVI screening 
In all potential candidates to TAVI, we performed a diagnostic screening in order to 
evaluate the eligibility to transcatheter procedure and to choose the most 
appropriate vascular access. Patient screening included: 
1) Blood tests; 
2) Chest radiography; 
3) Electrocardiogram; 
4) Transthoracic and transesophageal echocardiogram, 
5) Complete left heart catheterization, including coronary angiograms, LV 
angiography, angiograms of ascending and abdominal aorta and iliac-femoral 
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arteries. These angiograms were performed with a 5F pigtail catheter for a precise 
determination of vascular size. 
6) A multi-slice computed tomography (CT)-scan of aortic root, ascending and 
abdominal aorta, and iliac-femoral axis was performed for patients without 
contraindications. 
7) Doppler ultrasound evaluation of carotid and vertebral arteries; 
8) Pulmonary function test. 
In particular, all the variables collected by transthoracic and sometime 
transesophageal echocardiograms, complete heart catheterization and angiographies 
and CT-scan are listed in the following table 5, 6 and 7, respectively. 
Table 5 Echocardiographic parameters 
Aortic dimensions 
                                                       Aortic annulus (mm) 
Aortic root, height, depth (mm) 
                                                       Sino-tubular junction (mm) 
                                                       Tubular aorta (mm) 
Valve characteristics 
                                                      Calcium score (1-4+/4) 
                                                      Anatomic valve area (cm2) 
Left and right atrium 
                                                     Cranial – caudal diameter (mm) 
                                                     Antero-posterior diameter (mm) 
                                                     Transverse diameter (mm) 
                                                     Area (cm2) 
                                                     Volume (ml/m2) 
Left ventricle 
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                                                     End-diastolic diameter (mm) 
                                                     End-systolic diameter (mm) 
                                                     End-diastolic volume (EDV) (ml) 
                                                     EDV indexed (ml/m2) 
                                                     End-systolic volume (ESV) (ml) 
                                                     End-systolic volume indexed (ml/m2) 
                                                     EF (%) 
Right ventricle 
                                                     End-diastolic area (mm) 
                                                     End-systolic area (mm) 
                                                     Tricuspid annular plane systolic excursion (mm) 
                                                     Shortening fraction (%) 
Doppler 
                    Aortic valve 
                                                     Peak transvalvular gradient (mmHg) 
                                                     Mean transvalvular gradient (mmHg) 
                                                     AVA (cm2) 
                                                     Aortic regurgitation  
                    Mitral valve 
                                                     Peak transvalvular gradient (mmHg) 
                                                     Mean transvalvular gradient (mmHg) 
                                                     Mitral valve area (cm2) 
                                                     Mitral regurgitation  
                    Tricuspid valve 
                                                     Tricuspid regurgitation 
                                                     Pulmonary artery systolic pressure (mmHg) 
Diastolic function 
                                                     E and A wave velocity 
                                                     E/A ratio. 
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Table 6 Angiographic parameters 
Left ventricle angiography (RAO 30°) 
                                                       EDV index (ml/m2) 
                                                       ESV index (ml/m2) 
                                                       Stroke volume (ml) 
                                                       EF (%) 
                                                       Mitral regurgitation (0-4+/4) 
Supra-aortic angiogram (RAO 30° and LAO 60°) 
                                                       Aortic annulus (mm) 
                                                       Aortic root (height and depth, mm) 
                                                       Sino-tubular junction (mm) 
                                                       Ascending aorta (tubular, mm) 
                                                       Abdominal aorta – iliac-femoral arteries 
                                                      Size of common iliac arteries, external iliac arteries,  
                                                      Common femoral arteries (mm) 
                                                      Calcium score (0-4+/4) 
                                                      Degree of tortuosity (0-4+/4) 
                                                      Minimal luminal diameter and degree of stenosis 
                                                       Subclavian arteries: diameter, tortuosity and 
                                                       calcification 
Selective coronary angiograms: 
                                                      Minimal luminal diameter and degree of stenosis 
 
Table 7 MultiSlice CT scan 
Ascending aorta dimensions and degree of calcifications 
                                                      Aortic annulus (mm) 
                                                      Aortic root (height, depth, mm) 
                                                      Sino-tubular junction (mm) 
                                                      Ascending aorta (tubular, mm) 
                                                      Aortic arch (mm) 
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Valve characteristics 
                                                      Calcium score (1-4+/4) 
                                                      Anatomic AVA (cm2) 
Coronary ostia height respect to annular plane 
Abdominal aorta and iliac-femoral arteries 
                                                      Size (mm) 
                                                      Calcium score (0-4+/4) 
                                                      Degree of tortuosity (0-4+/4) 
                                                      Degree of stenosis 
Subclavian arteries: size, tortuosity and degree of calcifications and stenosis 
 
 
9.3 Description of procedure 
In transfemoral approach, in beginning we have started the device implantation with 
surgical exploration of femoral artery. However, in majority of patients, totally 
percutaneous TF closure was performed under mild sedation and local anaesthesia. 
A pre-closure of the common femoral artery puncture site is done before 
introduction of the sheath using the Prostar XL devices (Abbott Vascular Devices, 
Redwood City, California) [52]. 
Transapical approach is usually performed under general anaesthesia and 
endotracheal intubation. An anterolateral minithoracotomy, usually in the fifth or 
eventually in the sixth intercostal space, is performed. Two circular purse-string 
sutures are placed on the cardiac apex. The procedure itself starts with an apical 
puncture. At the end of procedure, the apical puncture site usually can be safely 
secured by tying the purse-string sutures [58]. 
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With the transubclavian approach, procedures are generally performed under 
general anaesthesia with double-lumen intubation in the catheterization laboratory. 
Cardiac surgeons perform a surgical cut-down to isolate the left subclavian artery 
just below the subclavian bone. After the procedure, the subclavian artery is 
restored by direct suture [56,59]. 
For all the described approaches, a supra-aortic angiogram is always performed in 
LAO 40° projection to evaluate the presence and degree of aortic regurgitation. A 6-F 
sheath was percutaneously placed in the opposite femoral artery through which a 6-
F pigtail was advanced in the ascending aorta for hemodynamic monitoring and 
landmark aortic angiography. A catheter for temporary pacing was advanced 
through the opposite site femoral vein in the right ventricle. 
For the more commonly used TF retrograde approach, the native aortic valve is then 
crossed with a straight 0.035-inch guide wire using an Amplatz Left-1 or 2 coronary 
catheter advanced to the ascending aorta in the LAO 40° projection. 
The transvalvular gradient is measured. After then, a 260 cm long, 0.035" Amplatz 
Super Stiff J Guidewire® (COOK) pre-shaped into its distal floppy portion is advanced 
into the left ventricle. A high-pressure and semi-compliant balloon catheter (Cristal 
Balloon, BALT, Montmorency, France) is introduced over the wire. A valve dilatation 
is performed using manual injection with a regular Luer-lock syringe during rapid 
ventricular pacing (200 to 220 stimulations/min). Pacing is achieved using a 
temporary lead placed into the right ventricle through the femoral vein. 
After inflation, the balloon is removed maintaining the guide in place. The valve, 
crimped onto his catheter, is introduced on the same guide-wire by retrograde 
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approach till the native aortic valve. The supra-aortic angiogram and native valve 
calcifications are used as anatomical landmarks for valve placement. SE valves are 
deployed step-by-step during normal heart beating while balloon expandable valves 
are deployed during rapid pacing. Hemodynamic improvement is measured 
immediately afterwards, and a supra-aortic angiogram is performed in patients 
without renal insufficiency to assess the presence, location, and degree of aortic 
regurgitation and the patency of the coronary arteries, as well as to rule out 
complications, such as aortic dissection. Heparin at a dose of 100 IU/kg body weight 
is administered to yield an activated clotting time of 250-300 seconds throughout 
the procedure and after the procedure, the heparin was neutralized by protamine. 
Patients were pre-medicated with aspirin, clopidogrel, and vancomycin or 
teicoplanin. 
 
9.4 Post-TAVI monitoring and management 
After TAVI, patients remained in the cardiac intensive care unit for at least 24 hours 
and are closely monitored for 48-72 hours with particular attention to hemodynamic 
balance, vascular access, renal function, infections and eventual onset of cardiac 
conduction disturbances (especially late atrioventricular block). A transthoracic 
echocardiography was performed 24-48 hours after the procedure and pre-
discharge. Twelve-lead electrocardiography was performed daily during 
hospitalization. A chest X-ray was performed during the first 24 hours after TAVI and 
according to clinical need after then. Blood tests were carried out every 8 hours the 
first day, then every 12-24 hours (troponin I, blood count, LDH, haptoglobin, total 
55 
 
and fractional bilirubin, BUN, creatinine, PT, PTT, INR, AT III). After the procedure, a 
dual antiplateled regimen of aspirin 100 mg and clopidogrel 75 mg daily for 3 to 6 
months, after which 100 mg of aspirin daily was prescribed indefinitely. 
 
9.5 Follow up 
Clinical and echocardiographic follow-up was data were collected at 1, 3, 6, and 12 
months and yearly thereafter. The clinical follow-up events included death from all 
causes, cardiac death (including all unexplained deaths), acute myocardial infarction, 
stroke, cardiac heart failure requiring rehospitalization, and PPM implantation. 
Functional status was evaluated according to New York Heart Association (NYHA) 
classification. At each temporal step, a 12-lead electrocardiogram was collected in all 
patients, to record modifications in atrioventricular and intraventricular conduction. 
Prosthesis function (peak and mean transvalvular gradient, peri- or intra-prosthetic 
leakage) as well as chamber size and function and other valvulopathies were also 
evaluated using transthoracic echocardiography. 
9.6 Definitions 
Device success, cardiovascular mortality, myocardial infarction, stroke, life-
threatening or disabling bleeding, acute kidney injury (AKI) and vascular 
complications were defined according to Vascular Academic Research Consortium 
(VARC) definitions [60]. Procedural success was defined as the device success 
without urgent cardiac surgery and/or intraprocedural death. Peri-procedural death 
was defined as any death within 30 days after the procedure or any death before 
discharge. 
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10. Statistical analysis 
 
Categorical data are expressed as numbers and percentages and compared by 
Fisher’s or X2 exact test as appropriate; continuous variables are expressed as mean 
± standard deviation (SD). Differences between means of continuous variables were 
tested by one way analysis of variance. Repeated measures of continuous variables 
at different time points were compared by repeated measures analysis of variance. 
Multiple stepwise logistic regression analyses of significant variables at univariate 
analysis were performed to identify independent predictors of events. Odds ratios 
(ORs), hazards ratios (HR) and their corresponding 95% confidence intervals (CIs) are 
provided. Cumulative survival curves were drawn using the Kaplan-Meier method, 
and the log-rank test was used to compare differences between groups. A p value 
<0.05 with a 2-tailed test was considered statistically significant. Other specific tests 
are described in each section of results. Statistical analysis was carried out using the 
statistical software SPSS version 17.0 for Windows (SPSS, Inc., Chicago, Illinois). 
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11. Results 
 
 
11.1 Global population  
We prospectively enrolled 72 patients affected by severe symptomatic AS or aortic 
bio-prosthesis dysfunction referred to university hospital, Verona between March 
2010 and March 2013 for TAVI, because of high surgical risk or inoperability criteria, 
after discussion with the Heart Team. Clinical and demographic characteristic of the 
study population was showed in Table 8. Mean age of population was 81.9 + 6.3 year 
with range of 53 - 91 year. Among them 37 (51.4%) were female, 34 (47%) were 
overweight (BMI 25-29.9) and 6 (8.3%) were obese (BMI>30%). Majority of patients 
suffered from chronic arterial hypertension 60 (83.3%). Diabetes, dyslipidemia and 
chronic obstructive pulmonary disease was present in 19(26.4%), 68 (94.4%) and 
18(25%) respectively. 
According to EuroSCORE I, 34 (47.2%) patients were labelled as high surgical risk 
(logistic euroSCORE >20%). However, with EuroSCORE II only 10 (13.9%) of patients 
were consider high risk for surgical treatment (euroSCORE II >20%). There was 
statically significant difference in calculation of mean euroSCORE II and mean 
euroSCORE I (11.40 + 11.38 % vs 26.86 + 18.42 %; p<0.001) for the overall 
population. EuroSCORE I was overestimated risk of intervention in general 
population. 
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Table 8 showing clinical and demographic parameters of general population 
Variables Total population(n=72) 
Age, years ± SD 81.9 ± 6.3 
Female gender, n (%) 37 (51.4%) 
Weight, mean + SD 69.2 + 11.8 
BMI, mean + SD 
                                 Normal weight (BMI < 24.9), n (%) 
                                 Overweight (BMI 25-29.9); n (%) 
                                 Obese (BMI >30), n (%) 
25.37 + 3.93 
32 (44.4%) 
34 (47%) 
6 (8.3%) 
Height(m), mean + SD 1.65 + 0.09 
Systolic Blood Pressure (mmHg), mean + SD 129 + 20 
Hypertension, n (%) 60 (83.3) 
Diabetes, n (%) 19 (26.4) 
Dyslipidemia, n (%) 68 (94.4) 
COPD, n (%) 18 (25) 
Previous CAD, n (%) 43 (59.7) 
History of PCI, n (%) 31 (43.1) 
History of CABG, n (%) 17 (23.6) 
Atrial fibrillation, n (%) 29 (40.3) 
Previous stroke, n (%) 6 (8.3) 
Peripheral artery disease, n (%) 37 (51) 
Porcelain Aorta, n (%) 5 (6.9) 
Serum Creatinine, mean + SD 1.49 + 0.98 
Creatinine clearance(mL/min), mean + SD 41.04 + 14.20 
Euroscore I, % + SD 26.86 + 18.42 
Euroscore II, % + SD 11.40 + 11.38 
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In this series of patients, most common presentation for aortic valve disease was 
stable angina 43 (55.6%). Second most common presentation was syncope 38 
(52.8%) which was followed by cardiac failure 27 (37.5%) and nearly 60% patients 
has NYHA class III/IV as demonstrated in table 9. 
 
Table 9 Symptoms before TAVI 
Variables Total population (n=72) 
Syncope, n (%) 38 (52.8) 
Unstable angina, n (%) 2 (2.8) 
Stable angina, n (%) 43 (59.7) 
NYHA class 
I, n(%) 
II, n (%) 
III, n (%) 
IV, n (%) 
 
1 (1.4) 
28 (38.9) 
40 (55.6) 
3 (4.2) 
Cardiac failure, n (%) 27 (37.5) 
 
 
Four (5.6%) patients were undergoes balloon aortic valvuloplasty (BAV) before TAVI 
as bridge to TAVI, majority of them presented in emergency as critically ill clinical 
condition. Staged TAVI was performed after clinical and hemodynamic stabilization 
of patient. In three (4.2%) patients, percutaneous coronary artery intervention 
performed along with BAV for critically coronary artery disease. Even two (2.8%) 
patients underwent carotid artery stenting for critical carotid artery disease before 
TAVI. 
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Every patient underwent thorough baseline trans-thoracic echocardiographic to 
evaluate severity of stenosis, measurement of aortic valve annulus and left 
ventricular systolic and diastolic dysfunction. Baseline echocardiographic finding are 
presented in Table 10. 
 
Table 10 Baseline echocardiography 
Variables Total population (n=72) 
Aortic annulus (mm) mean  + SD 21.30 + 1.73 
Aortic valve area (cm2/m2), mean + SD 0.56 + 0.23 
Peak gradient (mmHg), mean + SD 68.61 + 23.13 
Mean gradient (mmHg), mean + SD 42.1 + 16.2 
Inter-ventricular septum thickness (cm), mean + SD 1.6 + 0.24 
LVEF, % + SD 
Good (EF >50%), n (%) 
Detoriated (EF <50%), n (%) 
52.4 + 14 
43 (59.7) 
29 (40.3) 
Mean pulmonary artery pressure, mean + SD 
   Normal/mild PHT (<30 mmHg), n (%) 
Moderate PHT (31-55mmHg), n (%) 
                       Severe PHT (>55mmHg), n (%) 
45.53 + 16.23 
15 (20.8) 
37 (51.4) 
20 (27.8) 
Aortic valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
Grade-4, n (%) 
 
24 (33.3) 
37 (51.4) 
8 (11.1) 
2 (2.8) 
1 (1.4) 
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Mitral Valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
 
10 (13.9) 
52 (72.2) 
9 (12.5) 
1 (1.4) 
 
 
TAVI was performed in fifty eight (80.6%) patients for the severe, symptomatic aortic 
valve stenosis, in four (5.6%) patients for aortic valve insufficiency and ten patients 
(13.9%) have both stenosis-insufficiency complex but stenosis component was more 
severe than insufficiency. Table 11 demonstrated procedural detail. At our centre, 
transfemoral approach was used more frequently 60 (83.3%) as compare to 
transapical 11 (15.3%), because has low surgical risk and periprocedural 
complications. Trans-apical approach was preferred in patients with severely 
calcified ilio-femoral axis, aortic tortousity and calcification. Sub-clavian approach 
was used only in single patient who was presented with severe calcified, tortuous 
ilio-femoral axis along with deformities of thoracic cage.  
Among the patient with trans-femoral approach, initially, we started with surgical 
exploration followed by closure with surgical purse string suture of femoral artery, 
however, after performing 10 (17.8%) patients, we have started to apply suture 
mediated percutaneous closure device (Prostare XL) in almost all patients and 
surgical exploration remained for the patients with severely calcified, tortuous and 
small femoral arteries. Among a 40 (65.6%) trans-femoral approach closed with 
suture mediated device, four (10%) patients showed significant stenosis at device 
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closure site which was treated with peripheral angioplasty balloon dilatation. Single 
patient needed stent implantation. However, three (7.5%) showed small leak at 
device closure site two of them was treated with manual compression of femoral 
artery and one patient needed covered stent implantation.  
An Edward- Sapien was most commonly used device at our centre 59 (81.9%), Core-
Valve was implanted exceptional in 13 (18.1%) patients mostly with aortic 
insufficiency, big aortic annulus or vascular and aortic root anatomy which not 
suitable for Edward- Sapien device. Size of prosthesis and other details were showed 
in table 11. Pre-prosthesis implantation valvuloplasty was performed in most of the 
patient to remove the aortic valve stenosis and break the calcified aortic leaflet ring, 
however, in four patients balloon valvuloplasty was not performed; due to severe 
aortic valve insufficiency without calcification (2 patients), one with malfunctioning 
aortic valve prosthesis and another with big aortic annulus without calcification.  
According to VARC, first prosthesis implantation was unsuccessful in 5(6.9%). The 
most common causes of failure was severe aortic insufficiency; due to small 
prosthesis [However, it was only largest prosthesis available for clinical use (1 
patient)]; low implantation (1 patient); high implantation (2 patients) and finally, 
implantation of prosthesis in thoracic aorta due to difficulty in passing device 
through severely tortuous and calcified aortic arch which leads to dislodgement of 
the prosthesis. In case of moderate to severe aortic insufficiency after prosthesis 
implantation, post-dilatation of prosthesis was performed with valvuloplasty balloon 
with appropriate size in 9 (12.7%). 
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Table 11 TAVI procedural details 
Variables Total population (n=72) 
Aortic valve etiology for TAVI 
                              Aortic stenosis, n (%) 
                              Aortic insufficiency, n (%) 
                             Aortic stenosis + Aortic insufficiency, n (%) 
 
58 (80.6) 
4 (5.6) 
10 (13.9) 
Approach for TAVI 
                          Trans-femoral, n (%) 
                          Trans-apical, n (%) 
                          Sub-clavian, n (%) 
 
60 (83.3) 
11 (15.3) 
1 (1.4) 
Closure used for Trans-femoral and sub-clavian approach 
                          Surgical, n (%) 
                          Suture mediated closing device, n (%) 
 
21 (34.4) 
40 (65.6) 
Type of Valve prosthesis 
                         Edward- Sapien, n (%) 
                         Core-Valve, n (%) 
 
59 (81.9) 
13 (18.1) 
Size of aortic prosthesis 
23mm, n (%) 
26mm, n (%) 
29mm, n (%) 
31mm, n (%) 
 
26 (36.1) 
33(45.8) 
10(13.9) 
3(4.2) 
Valvuloplasty done before deployment of prosthesis, n (%) 68(94.4) 
First Valve implantation successful, n (%) 
First Valve implantation unsuccessful, n (%) 
Causes of unsuccessful valve implnatation 
Severe Aortic insufficiency (small size of prosthesis), n 
Severe Aortic insufficiency (low deployment of prosthesis), n 
Severe Aortic insufficiency (high deployment of prosthesis), n 
Valve implanted in thoracic aorta, n 
67(93.1) 
5(6.9) 
 
1 
1 
2 
1 
Post-dilatation after prosthesis implantation, n (%) 9 (12.7) 
Amount of contrast (ml), mean + SD  143.54 + 60.29 
Fluoroscopy time (min), mean + SD 20.8 + 11.2 
Procedure time (min), mean + SD 111.3 + 39.6 
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11.2 Immediate peri-procedural outcome 
Immediate peri-procedural all cause complications found in 35 (48.6%), among them 
vascular complications were most frequent 14 (41.2%), moderate to severe aortic 
valve insufficiency found in 7 (20.6%), conduction blockage in 4 (11.8%) and finally 
most important complication noted in our series is thrombus like structure around 
the implanted prosthesis 4(11.8%). These special cases were managed with infusion 
of intravenous heparin, controlled echocardiography every 24 hours. In almost all 
patients thrombus resolves spontaneously after few days. However, one patient 
showed persistence of thrombus which complicated as cerebral stroke at 3 month 
follow up. One patient died during procedure. After deployment of prosthesis, 
ventricular fibrillation started, which change to asystole even after cardio-pulmonary 
resuscitation. Post-mortem report showed occlusion of right coronary ostium with 
thrombus. Occlusion of right coronary artery with ruptured calcified tissue during 
balloon valvuloplasty and prosthesis deployment which leads to acute myocardial 
infarction manifesting as arrhythmia is reasonable explanation. Other peri-
complications are showed in Table 12. 
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Table 12 peri-procedural immediate complications 
 
Variables Total population (n=72) 
All-cause immediate complications, n (%) 
Vascular complications, n (%) 
Aortic insufficiency (Moderate-severe), n(%) 
Bundle branch block, n 
Thrombus around implanted prosthesis, n (%) 
Death, n(%) 
Stroke, n (%) 
Ventricular fibrillation, n (%) 
Hypotension, n (%) 
Prosthesis implantation in thoracic aorta, n (%) 
Thrombus in left atrium, n (%) 
35 (48.6) 
14 (41.2) 
7 (20.6) 
4 (11.8) 
4 (11.8) 
1(2.9) 
1 (2.9) 
1 (2.9) 
1(2.9) 
1(2.9) 
1 (2.9) 
 
 
Every patient after TAVI was monitored in intensive care unit for minimum six hours. 
Mean ventilation time was 277.8 + 1004.7 min (range= 70-8640 min). In trans-
femoral setting, on table extubation was performed in almost all patients. 24 hour 
mean blood loss was 184.2 + 188.5 ml.  Moreover, 29 (40.3%) patients needed red 
blood cell transfusion in peri-procedural period. Mean recovery in intensive therapy 
unit was 2.3 + 1.7 days (range=1-10 days) and total hospital recovery was 14.4 + 9.7 
days (range=4-59 days). 
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11.3 Outcome at 30days 
All patients were followed with routine ECG, echocardiography and laboratory 
investigation at 30 days after procedure. All cause mortality was 3 (4.2%) among 
these cardiovascular mortality was one (33.3%) and non-cardiac mortality was 2 
(66.7%). One patient died due to acute myocardial infarction which leads to 
ventricular fibrillation, another one with severe bleeding form apical puncture site 
which was worsened even after apical puncture site revision and last one was died 
due to massive cerebral haemorrhage and non responsive hypertension.  
Vascular access site hematoma was found in 15 (20.8%) of patients. Vascular 
complications like major bleeding and hematoma, limb ischemia were most 
commons 29 (40.1%) like other multicentre series. Three (4.2%) patients suffered 
from cerebral stroke. One cerebral stroke resolve spontaneously remaining two 
complicated with disability. Five (6.9%) patients needed permanent pacemaker 
implantation due to conduction abnormality after prosthesis deployment. Among 
them majority were with Core-Valve 60%. 
Transthoracic echocardiography at 30 days was performed in remaining 69 patients 
which showed marked decrease in peak gradient from 68.6 + 23.1 mmHg to 16.3 + 
7.2 mmHg (p<0.001), mean gradient decrease from 42.2 + 16.2 mmHg to 8.7 + 3.9 
mmHg (p<0.001) and mild improvement in left ventricular function from 52.4 + 14 % 
to 53.75 + 13.35% which was not significant (p=0.10) as showed in table 13 and 
figure 10 and 11. 
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Table 13 Trans-thoracic echocardiography at 30 days post-TAVI 
 
Echo parameters 
Total Baseline 
population 
(n=72) 
Total population 
at 30 days FU 
(n=69) 
P 
Value 
Aortic valve area(cm2/m2), mean + SD 0.56 + 0.23 1.82 + 0.30 <0.0001 
Peak gradient(mmHg), mean + SD 68.61 + 23.13 16.3 + 7.15 <0.0001 
Mean gradient(mmHg), mean + SD 42.1 + 16.2 8.71 + 3.87 <0.0001 
Inter-ventricular septum thickness(cm), 
mean + SD 
1.6 + 0.24 1.54 + 0.22 <0.001 
Left Ventricular ejection fraction(%), 
mean + SD 
52.4 + 14.1 53.75 + 13.35 0.103 
Aortic valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
Grade-4, n (%) 
 
24(33.3) 
37(51.4) 
8(11.1) 
2(2.8) 
1(1.4) 
 
9(12.5) 
56(77.8) 
4(5.6) 
0(0) 
0(0) 
 
 
0.54 
Mitral valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
 
10(13.9) 
52(72.2) 
9(12.5) 
1(1.4) 
 
7(9.7) 
50(69.4) 
12(16.7) 
0 
 
 
0.32 
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Figure 10 showing marked decrease in peak gradient 
 
 
 
Figure 11 showing small improvement in left ventricular function 
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11.4 Long term follow up 
Recently long term follow up was performed in all 69 (100%) patients remained alive 
after 30 days follow up. Mean duration of follow up was 13.19 + 9.7 month (range 3-
35 months). All cause mortality was found in 11 (15.9%), among them cardiovascular 
and non-cardiovascular mortality was found in 4 (36.36%) and 7 (63.63%) patients 
respectively. One patient (1.45%) underwent heart transplantation which was on 
heart transplantation list for severe left ventricular failure. A composite outcome 
(death and re-hospitalization) was found in 32 (44.4%). Bleeding complication, 
cerebral stoke and re-hospitalization in the patients alive at follow up was showed in 
table 14. 
 
Table 14 Re-hospitalization 
Variable Population (n=77) 
Re-hospitalization 
Cardiac causes, n (%) 
Non-cardiac causes, n (%) 
18(31.6) 
4(22) 
14(78) 
Cardiac failure, n (%) 
Cardiac and renal failure, n (%) 
Cerebral stroke, n (%) 
Respiratory insufficiency, n (%) 
Respiratory tract infection, n (%) 
Hepatic failure, n (%) 
Septicaemia, intestinal ischemia, n (%) 
Anaemia, n (%) 
Intervention of carotid end-arteriotomy, n (%) 
Constipation, n (%) 
 
3(16.67) 
1(5.5) 
3(16.67) 
4(22.22) 
2(11.11) 
1(5.5) 
1(5.5) 
1(5.5) 
1(5.5) 
1(5.5) 
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Table 15 Long term follow up  
Variables Total population (n=57) 
Bleeding complications, n (%) 12(21) 
Cerebral stroke, n (%) 3 (5.3) 
NYHA class 
I, n (%) 
II, n (%) 
III, n (%) 
IV, n (%) 
 
10(17.5) 
28(49.1) 
18(31.6) 
1(1.8) 
Frality Scale 
0, n (%) 
1, n (%) 
2, n (%) 
3, n (%) 
 
22(38.6) 
2(3.5) 
27(47.4) 
6(10.5) 
 
There was marked improvement in NYHA class  as showed in table 15 and figure 12 
and 13 on long term follow up. Most of patients shifted to lower NYHA class than 
baseline NYHA class. 
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Figure 12 showed decrease in NYHA class on long term follow up 
 
 
Figure 13 showed how the NYHA class shifted from higher class to lower class 
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11.5 Survival analysis 
Figure 14 and 15 showed survival analysis performed using Kaplan-Meier curve 
stratifying with heart failure and high euroSCORE. 
 
Figure 14  shows KM curve stratified with heart failure 
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Figure 15 demonstrated nature of KM curve for all cause mortality with high 
euroscore II on long term follow up 
 
 
Moreover, high Euroscore-II predict more accurately mortality as compare to high  
logistic Euroscore I (p<0.002; CC= 0.375) showed by Kaplan-meier hazard curve as 
showed in figure 16 and figure 17. 
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Figure 16 showing hazard curve stratified with high logistic euroscore 
 
 
Figure 17 showing hazard curve for mortality stratified with high euroscore II 
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11.6 Long term performance of prosthesis 
Echocardiographical follow up was present in all 57 patients alive at long term follow 
up. Peak gradient remained decrease from 68.61 + 23.13 mmHg at baseline to 18.9 + 
6.4 mmHg at follow up (p<0.001); even mean gradient remained decrease from 42.1 
+ 16.2 mmHg to 9.9 + 3.4 mmHg (p<0.001), improvement in left ventricular ejection 
fraction from baseline 52.4 + 14 % to 60.3 + 12.12 %(p<0.001) was significant as 
compare to 30 days follow up. Pulmonary artery mean pressure was decrease from 
45.33 + 16.23 mmHg at baseline to 37.4 + 14.3 mmHg (p=0.01) significantly than 30 
days follow up. There was mild increase in PG and mean gradient as compare to 
parameter at 30 days follow up but was not statistically significant. Other 
parameters are showed in table 16 and figure 18. 
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Table 16 Echocardiographic performance of prosthesis 
 
Echocardiography 
parameter 
Baseline 
population 
(n=72) 
Population at 
30 days FU 
(69) 
Population at 
long term FU 
(n=57) 
P for 
baseline 
and LTFU 
Peak gradient(mmHg), 
mean + SD 
68.61 + 23.13 16.3 + 7.2 18.9 + 6.4 <0.0001 
Mean gradient(mmHg), 
mean + SD 
42.1 + 16.2 8.71 + 3.87 9.9 + 3.4 <0.0001 
PAP (mmHg), mean + SD 45.33 + 16.23 42.28 + 14.20 37.4 + 14.3 0.001 
LVEF (%), mean + SD 
EF >50%, n (%) 
EF <50%, n (%) 
52.4 + 14 
43(59.7) 
29(40.3) 
53.75 + 13.35 
44(63.8) 
25(36.2) 
60.3 + 12.12 
46(80.7) 
11(19.3) 
<0.001 
0.001 
0.001 
Aortic Valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
Grade-4, n (%) 
 
24(33.3) 
37(51.4) 
8(11.1) 
2(2.8) 
1(1.4) 
 
9(12.5) 
56(77.8) 
4(5.6) 
0(0) 
0(0) 
 
19(33.3) 
31(54.4) 
7(12.3) 
0(0) 
0(0) 
 
 
0.44 
Mitral Valve insufficiency 
No, n (%) 
Grade-1, n (%) 
Grade-2, n (%) 
Grade-3, n (%) 
 
10 (13.9) 
52 (72.2) 
9 (12.5) 
1 (1.4) 
 
7(9.7) 
50(69.4) 
12(16.7) 
0(0) 
 
1 (1.8) 
40 (70.2) 
12 (21.1) 
4 (7) 
 
 
0.004 
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Figure 18 showed improvement in trans-aortic gradient, LVEF and PAP 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
Figure 19 showed changes in aortic valve insufficiency at baseline, 30 days and long 
term follow up 
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Figure 20 showed changes in mitral valve insufficiency at baseline, 30days and long 
term 
 
 
 
Predictor of mortality at long term was found to be high Euroscore II OR= 6.15 (CI 
1.1-34.1); p<0.04, obesity( BMI>30) OR=22(3.34-150); p<0.001. 
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11.7 Incidence, predictor factors and prognostic implication of acute kidney 
injury (AKI) produced after TAVI procedure 
 
TAVI candidates are mostly elder patients suffering from chronic kidney disease. 
Kidney function may be worsened after use of contrast during the TAVI. Aim of this 
analysis is to evaluate the incidence of AKI, predictors and prognostic value of same 
in long term follow up.  
PreTAVI serum creatinine was defined as value of serum creatinine immediately 
before TAVI. Highest level of creatinine in first week after TAVI was considered as the 
post-TAVI serum creatinine. Creatinine clearance was calculated according to the 
Cockgroft-Gault equation, based on s. creatinine, age, sex and weight of the patient. 
In this analysis more than 20 % decline in creatinine clearance value or need for 
haemodialysis after procedure was considered as AKI (RIFLE criteria) [61].  
We analysed 69 patients operated for severe aortic valve disease during Febraury 
2010- Febraury 2013 at our centre. According to development of acute kidney injury, 
population is divided into two groups; AKI present and AKI absent. Clinical and 
demographic characteristics of both groups are showed in table 10.  
Incidence of AKI was 21.7% in this small group of population. There was no 
difference in the clinical presentation, demographic characteristic, co-morbidities 
and other peri-operative parameters. Amount of contrast used during procedure 
was higher in group with AKI than without AKI (156 + 65 vs 143.3 + 58.2; p=0.34). 
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Table 17 clinical and demographic characteristic of AKI present and AKI absent 
group 
Variables AKI present 
(n=15) 
AKI absent 
(n=54) 
P 
value 
Univariate analysis 
OR 95% CI 
Gender male, n (%) 5 (33.3) 28 (51.9) 0.16 1.16 0.72-3.3 
Age, mean + SD 83.5 + 5.2 81.9 + 6.2 0.99 0.01 -0.01-0.02 
BMI, mean + SD 24.7 + 3.2 25.6 + 3.8 0.51 -0.01 -0.04-0.02 
Overweight (BMI 25-29.9), n (%) 9 (60) 24 (44) 0.21 0.91 0.83-0.99 
Hypertension, n (%) 13 (86.7) 45 (83.3) 0.75 0.96 0.76-1.2 
Diabetes, n (%) 2 (13.3) 14 (25.9) 0.30 1.9 0.50-7.6 
COPD, n (%) 2(13.3) 15 (27.8) 0.25 2.1 0.53-8.1 
Baseline S. Creatinine , mean + SD 1.04 + 0.11 1.55 + 1.07 0.01 -0.1 -0.2-0.01 
Baseline Creatinine clearance, mean + SD 44.5 + 9.6 41.1 + 14.9 0.15 0.00 -0.00-0.01 
Coronary artery disease, n (%) 9 (60) 31 (59.3) 0.96 0.98 0.62-1.6 
Prior PCI, n (%) 6 (40) 23 (42.6) 0.86 1.1 0.53-2.1 
Prior CABG, n (%) 2 (13.3) 14 (25.9) 0.31 1.9 0.50-7.6 
Atrial fibrillation, n (%) 7 (46.7) 21 (38.9) 0.59 0.83 0.44-1.6 
Peripheral vascular disease, n (%) 6 (40) 28 (51.9) 0.41 1.3 0.66-2.5 
LVEF%, mean + SD 51.4 + 14.3 53.4 + 13.8 0.73 -0.02 -0.01-0.01 
Cardiac dysfunction (EF<50%), n (%) 7 (46.7) 20 (37) 0.50 0.8 0.42-1.5 
NYHA  
III, n (%) 
IV, n (%) 
 
10(71.4) 
0(0) 
 
29(53.7) 
3(5.6) 
 
0.40 
 
  
Euroscore logistic % + SD 25.28 + 14.5 27.5 + 19.7 0.08 -0.00 -0.01-0.00 
Euroscore II % + SD 8.4 + 4.4 12.2 + 12.7 0.05 -0.01 -0.01-0.04 
Peak gradient, mean + SD 66.3 + 25.14 69.45 + 23.3 0.97 0.00 -0.01-0.00 
Pulmonary artery pressure, mean + SD 44.33 + 12.24 45.44 + 17.44 0.03 0.00 -0.01-0.00 
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On univariate analysis only pre-TAVI s. creatinine, euroscore II and pulmonary artery 
pressure was predictor of development of acute kidney injury after TAVI procedure. 
On long term follow mortality was higher in patient group without AKI after TAVI 
(22% vs 0%; p=0.04). However, rehospitalisation for any cause was higher in AKI 
developed group (53.3 % vs 23.8%; p=0.03) as showed in table 18. 
 
Table 18 peri-procedural, 30days and long term FU  parameter in AKI present and 
AKI absent group 
Variables AKI present 
(n=15) 
AKI absent 
(n=54) 
P 
value 
Univariate analysis 
OR 95% CI 
Amount of constrast used, 
mean + SD 
156.7 + 65 143.2 + 58.2 0.34 0.001 -0.00-0.00 
Procedural time, mean + SD 101 + 29 113 + 42.3 0.25 -0.00 -0.00-0.00 
Stay in intensive therapy unit, 
day + SD 
2.3 +2.5 2.3 + 1.34 0.05 0.002 -0.06-0.06 
Stay in hospital, days + SD 13.8 + 10.4 15.1 + 9.5 0.80 -0.00 -0.01-0.00 
Immediate post TAVI 
complications, n (%) 
7 (46.7) 25(46.3) 0.98 1.0 0.54-1.8 
Long term outcome 
All cause mortality, n(%) 
Rehospitalisation, n (%) 
NYHA III, n (%) 
NYHA IV, N (%) 
Frality 
0, n (%) 
1, n (%) 
2, n (%) 
3, n (%) 
 
0(0) 
8(53.3) 
6(40) 
1(6.7) 
 
4(26.7) 
0(0) 
8(53.3) 
3(20) 
 
12(22.2) 
10(23.8) 
12(28.6) 
0(0) 
 
18(42.9) 
2(4.8) 
19 (45.2) 
3 (7.1) 
 
0.04 
0.03 
0.28 
 
 
 
0.34 
 
0.45 
 
0.22-0.9 
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Among the 57 patients remained alive at long term follow up, 16 (28%) showed the 
improvement in creatinine clearance after TAVI procedure. Improvement in renal 
function is considered as increase in > 20% of creatinine clearance on long term 
follow up. Insufficient renal perfusion in setting of severe aortic stenosis may be 
reason for this. 
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11.8 Feasibility and safety of TAVI in treatment of severe aortic regurgitation 
in patients with HEART MATE II 
TAVI has enhanced the therapeutic spectrum far beyond expected, and as 
stated before, with growing experience of the heart team, patients in difficult 
conditions and perhaps no other option, may benefit from “off label” use of 
transcatheter valves. In particular the versatility of the CoreValve allows the 
treatment of difficult cases of aortic regurgitation as the one presented below.     
A 53-year-old male patient with end-stage dilated cardiomyopathy was 
uneventfully implanted with a Thoracic HeartMate II left ventricular assistance 
device intended as a bridge to transplantation. Ten months post-operatively, he 
showed progressively worsening of symptoms. In view of the unfavourable 
anthropometric characteristics, any attempt to anticipate transplantation was 
unsuccessful for lack of appropriate donors. Ineffective ventricular assistance output 
enssued due to severe aortic regurgitation [Fig. 21A]. Pulmonary edema with 
desaturation, and major arrhythmias ultimately required endotracheal intubation 
and cardiopulmonary resuscitation. Since neither optimal medical therapy nor 
ventricular assistance adjustments provided hemodynamic stability, the Heart Team 
decided for emergency trans-catheter aortic valve implantation. 
Procedure: through an 18-F introducer, an extra-stiff guidewire was positioned in 
the left ventricle, and a 29-mm CoreValve (Medtronic, Milwaukee, Wisconsin) was 
implanted under fluoroscopy and echo control. Due to a moderate residual 
periprosthetic regurgitation [Fig. 21B], a second 29-mm CoreValve was deployed 
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within the previous valve prosthesis with minimal residual leak [Fig. 21C], and no 
complications. (of note, at the time of this procedure, the 31mm CoreVale was not 
yet available). The femoral access was repaired by the Prostar XL Closure device. The 
patient’s hemodynamics improved immediately after procedure. On discharge, 
echocardiography showed mild periprosthestic regurgitation. The patient was 
transplanted 6 months later.  
Figure 21. Life saving TAVI for aortic insufficiency in Heart Mate II                
 
A) preTAVI severe aortic  insufficiency, B) after first device implantation, C) after second 
device implantation 
 
Use of TAVI technique for severe aortic regurgitation in Heart Mate II resulted in a 
life-saving procedure that allowed management of an acutely occurred 
hemodynamic instability. Being the first, ever reported case of this nature, it has 
been published elsewhere [62]. 
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11.9 Feasabilty and safety of using “Limb-saving” contra-lateral implantation 
of a protection guide-wire in femoral access during TAVI 
The use of a totally percutaneous technique for trans-femoral TAVI has several 
advantages over the surgical exploration [52]. First is the spared time compared to 
the surgical preparation of the vascular access that requires, even for expert teams, 
more than 60 to 90 minutes to open and close the vascular access as compared to 
percutaneous the technique. Furthermore, it can be performed with local 
anesthesia, and allows rapid patient mobilisation after 2 or 3 days of the procedure, 
depending on the patinet’s general conditions.  However, a totally percutaneous 
management of the femoral access route requires accurate pre-intervention 
screening, confidence with the use of the Prostar closure device, experience with 
peripheral vascular interventions, and the availability of a wide array of dedicated 
material. We believe that all cases performed percutaneously with the pre-
implantation of the Prostar device must be prepared with a contralateral 
implantation of a safety guide-wire before the implantation of the introducing 
sheath. This wire warrants a rapid access to the true lumen of the iliac-femoral 
vessels in case of occlusion or vascular rupture before or after TAVI [Figure 22A].A 
present case below is one of example of such alternative. 
An 87-year old obese female with medical history of hypertension, type II diabetes 
mellitus and CKD was admitted in hospital with heart failure. A TTE showed severe 
aortic valve stenosis (PG-56mmHg, MG-38mmHg, AVA-0.3cm2/m2) with important 
left ventricular dysfunction (LVEF=35%). Coronary angiography showed mild 
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atherosclerotic disease, peripheral angiography visualized moderate atherosclerotic 
stenosis with severe degree of calcification. Logistic EuroScore was 45%. PreTAVI 
screening with TTE and CTscan showed the following measurement: aortic annulus-
21mm, CFA diameter 7mm and 8mm on right and left side respectively. Implantation 
of 26mm Edward Sapien XT prosthesis was planned. 
Procedure: The procedure was performed under general anaesthesia. The Prostar 
suture mediated closing device was implanted on the right CFA after positioning a 
0.018” extra-support, 200mm length guide wire (Control V, Boston Scientific Corp., 
Natick, Massachusetts) from the contralateral CFA. Due to the impossibility of 
advancing the 20F introducer sheath through the extra-stiff 0.035 wire, several 
balloon dilatations of increased diameters were performed on the external and 
common iliac arteries. The Edward Sapien XT prosthesis was then successfully 
deployed under rapid pacing. The delivery system was retrieved and puncture site 
was closed with Prostar device. The final angiographic control showed the total 
occlusion of the right iliac artery [Figure 22B]. A peripheral angioplasty balloon 
9x60mm was inflated at the occluded site over the contralateral “limb saving” guide 
wire with rapid recovery of blood flow along the right femoral artery [Figure 22C]. 
Due to the presence of dissection and residual stenosis, a 9x40mm self-expandable 
Wallstent (Boston Scientific Corp., Natick, MA) was inserted which resulted in normal 
flow [Figure 22D]. Further clinical evolution was un-eventful.  
The rapid access to the vascular entry site of the large introducer sheath from a 
contralateral “safety wire” allows relatively simple management of complications 
that, otherwise, may prove life threatening, or that may require emergency major 
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vascular surgery with potentially severe post-operation complications [63,64]. The 
positioning of a balloon at the point of the percutaneous access site for a trans-
femoral TAVI procedure from the contralateral vascular access allows for example 
the rapid interruption of bleeding in case of arterial rupture or failure of the Prostar 
suture, or the resolution of stenosis created by the closing device itself [Figure 22C]. 
When simple balloon inflations are not sufficient, naked stent implantation may 
become necessary (like in the previously described case, Figure 22D), or even in 
some more dramatic situations covered stents may be required like in the case of a 
95-year old lady that, despite apparently excellent vascular conditions, 
experimented a large rupture of the CFA after removal of the introducer sheath and 
Prostar closure [Figure 22E]. This potentially severe complication was easily 
managed with the rapid implantation of an 8x40mm self-expandable covered stent 
that permitted a rapid recover and uneventful hospital course [Figure 22F].  
 
 
 
 
 
 
Figure 22 Safety guide-wire from contralateral side for rescue peripheral artery 
angioplasty 
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A) 0.0018” guide wire in the rigth femoral artery advanced from the left femoral puncture 
(arrow); B) Occlusion of right external iliac artery; C) Angiography after balloon dilatation. 
Residual stenosis and dissection at puncture site (arrow); D) Angiography after implantation 
of self-expandable stent; E) Rupture of right common femoral artery.  Constrast media is 
evident outside the artery (arrow);F) Final angio after positioning a covered self expandable 
stent in ruptured right CFA. 
 
Vascular complications are common with calcified, atherosclerotic iliac-femoral 
arteries [63-67]. However, proper selection of patient and access route, and 
adequate preventive measures reduce the risk. Apparently “normal” iliac-femoral 
arteries may give rise to severe complications in the elderly. Insertion of a safety 
wire from the contralateral artery is a “must” when planning a totally percutaneous 
trans-femoral TAVI. 
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11.10 Feasabilty and safety of trans-femoral TAVI in patient with aorto-iliac 
endoprosthesis and severely tortuous and atherosclerotic accesses-“Railing 
tract” technique  
 
A symptomatic 82-year old male with a known severe AVS was admitted in 
emergency with episodes of syncope and overt heart failure. He was rejected for 
SAVR in view of a severe pulmonary disease with bilateral emphysematous lungs 
(GOLD classification stage III), left anterior descending coronary artery disease, 
moderate CKD and high EuroScore (43%). He had also severe PVD with previous 
implantation of an aortic-bi-iliac endo-prosthesis. Heart Team opted for a trans-
femoral approach because of the severe lung disease despite presence of an aortic-
bi-iliac endo-prosthesis and severe tortuosity of the ilio-femoral axes, determining 
an approximately 360° loop on the right external iliac artery and a 260° loop on the 
left side, respectively [Figure 23A and 23B].  
Procedure: TAVI was undertaken with surgical exposure of left CFA. An extra-stiff 
wire was inserted upwards through the CFA to straighten the left iliac tortuosity. The 
22F Edward introducer however, could not advance beyond the endoprosthetic part 
of left common iliac. After several attempts the introducer was removed, its tip was 
found damaged likely because of friction against the calcium and the struts of the 
endoprosthesis. Another extra-stiff wire was therefore advanced from the right 
brachial artery to the left SFA through a multipurpose catheter for additional 
support. A new 22F Edward introducer was finally advanced as “railing track” with 
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two extra-stiff wires [Figure 23C]. After conventional balloon valvuloplasty, a 23mm 
Edward-Sapien XT aortic valve was successfully implanted. The femoral access was 
surgically repaired without complications. 
Figure 23 Railing tract technique 
 
A) CT Scan showing aortic-bi-iliac endoprosthesis and severe tortuosity of the ilio-femoral 
axes; B) Angiography showing severely tortuous left ilio-femoral axis (arrow); C) Insertion of 
introducer over the extrastiffs guidewires, one from right brachial artery up to left common 
femoral artery, and one from the SFA (arrow). 
 
This case is a successful example of an extremely challenging trans-femoral TAVI, 
managed with a special technique in a patient with clear contra-indications to the 
femoral access, but with no alternative options. The technique of inserting a second 
extra stiff wire down from the right brachial artery up to the femoral artery together 
with an ascending extra stiff wire from the femoral access to the ascending aorta 
which acts as “railing track” may be useful in specific TAVI candidate [69]. 
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11.11 Safety and feasibilty of Core-Valve insertion without introducer sheath 
Positioning the large introducing sheath from the CFA to the aorta in patients with 
severe PVD is the most challenging step of the trans-femoral procedure in these 
patients.Technically,theEdwards-Sapien prosthesis should not be pushed out of the 
introducer sheath, if it has not been fully advanced up to the thoracic-abdominal 
aortic segment [52]. Indeed, the rigidity of the catheter and valve device unit may 
cause aortic wall rupture if strongly pushed in direct contact to the vessel without 
the protection of the sheath [Figure24A]. The CoreValve system instead, due to its 
particularly flexible structure and self-expanding stent, can “cautiously navigate” into 
the iliac arteries even without the protection of the introducer sheath, that being 
larger than the valve itself, may not advance into a severely calcified and stenotic 
iliac axe. This was the case of a 79-year old man with medical history of 
hypertension, dyslipidemia and smoking habit, with previous coronary artery bypass 
grafts (CABG) and aortic valve replacement with a Toronto 25mm biological 
prosthesis implanted 13 years before. He presented with heart failure due to severe 
aortic regurgitation, moderate AVS and well preserved LVEF (63%). Pre-TAVI 
screening showed important athero-calcific iliac-femoral vascular disease [Figure 
24B]. Logistic Euro Score was 30%, and he was scheduled for a 26mm trans-femoral 
CoreValve implantation. 
Procedure: TAVI was performed by surgical exploration of left CFA under general 
anaesthesia. The difficulty encountered was, as expected, to insert the 18F 
introducer through the left common iliac artery due to severe calcifications and 
diffuse stenoses. Aggressive balloon angioplasty was performed with 8x30mm and 
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10x40mm peripheral balloons [Fig. 24C] but no further advancement of the 18Fr was 
possible. Considering the low profile of the CoreValve, the device was carefully 
advanced through the iliac artery without introducer [Figure 24D]. A 26mm 
CoreValve was successfully implanted within the previous aortic valve prosthesis 
(valve in valve). The access site was repaired surgically without complications. 
Figure 24 Valve insertion without introducer 
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A) Fluoroscopic view showing ruptured abdominal aorta (arrow); B) Angiography showing 
tortuous and severely calcified ilio-femoral axis; C) Fluroscopic view showing iliac artery 
balloon dilatation; D) Fluroscopic view showing insertion of CoreValve delivery system 
without introducer (arrow) 
 
Treating patients with previous cardiac surgery is challenging, and in this particular 
case with a patent left internal thoracic bypass graft and a degenerated aortic bio-
prosthesis and important PVD the access site requires cautious evaluation. The 
CoreValve device offers an excellent alternative allowing negotiation of severely 
diseased iliac arteries without the need for fully implanting the large introducer 
sheath. This may be a valuable alternative to the more complex subclavian access, in 
particular in patients with a patent mammary bypass graft that may contraindicate 
the use of such vascular route.  
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11.12 How to manage patient accidental finding of left atrial thrombus in 
TAVI suite? whether to quite the play or we have some option? 
Cerebral stroke is the most dreadful complication of aortic valve interventions, either 
surgical or trans-catheter [51,55,63-68]. So far, dedicated devices to protect the 
cerebral circulation of TAVI patients are under development but still not available. 
Intra-cardiac thrombosis is a major contra-indication to TAVI due to the risk of 
thrombus embolization during rapid pacing and during energic post-arrhythmic 
beats [46,52]. 
An afrail 84-year old woman with hypertension, diabetes, chronic hepatic disease, 
chronic atrial fibrillation in oral anticoagulation and a previous CABG surgery was 
admitted for a recurrent episode of heart failure. TTE showed severe AS (MG- 
45mmHg, AVA- 0.4cmq/mq) and pulmonary hypertension. Coronary angiography 
showed patent bypass grafts, peripheral angiography showed 50% stenosis in 
severely tortuous left common iliac artery, however right iliac and femoral axis was 
free of significant stenosis. Euroscore was 59% and a trans-femoral TAVI with 23mm 
Edward- Sapien valve was scheduled. 
Procedure:  the procedure was started with general anaesthesia.TEE examination 
revealed a large thrombus of 5x10mm in the left atrium [Figure 25A]. Due to the 
high risk of cerebral emobilization during TAVI, two carotid embolic protection 
devices (EPI EZ. FilterWire, Boston Scientific Corp.) were placed into the right and left 
common carotid arteries through the right and left brachial arteries respectively 
[Figure 25B]. After implantation of a 23mm Edward- Sapien XT prosthesis, the intra-
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operative TEE showed properly positioned and well functioning aortic prosthesis and 
a persisting left atrial thrombosis. After closure of the femoral access site, the two 
carotid artery filters were retrieved without clear images of embolic debris. The 
patient was discharged in optimal clinical and hemodynamic conditions. 
Figure 25 Accidental left atrial thrombus detection in TAVI suite 
 
A) TEE showing thrombus in left atrium; B) Insertion of filter device in right carotid artery 
Cerebral stroke is the most severe complication of TAVI, a persistent data that 
emerges from either randomized studies and large Registries [51,55,63-68]. An Intra-
cardiac thrombus is an absolute contra-indication for TAVI [52]. Usually during TAVI 
screening, transthoracic echocardiography is not sensitive for intracardiac thrombus 
detection. The reported case is an example of accidental left atrial thrombus 
detection and its management in the catheterization suite. Placing two embolic 
protection filters is technically challenging and time consuming. A dedicated device 
to protect the brain from embolic debris is still an unmet need of TAVI that requires 
urgent development from the Industry to further enhance safety of TAVI. 
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11.13 How to overcome coronary oclusion found during balloon 
valvuloplasty: Challenges from the coronary arteries take off. Is it safe to put 
protection guide wire in high risk coronary? is there possibilty for 
introduction of angioplasty catheter on wire? 
Coronary artery occlusion is a dreadful complication of TAVI and it has been reported 
in 0.4% to 1% of cases with either Edwards-Sapien and CoreValve systems 
[46,51,55,63-68].  Accurate pre-TAVI diagnostic screening is, again, a crucial step to 
avoid this complication. In particular, CT scan measurements from the aortic annulus 
to the coronary take off should be performed in all cases before considering a 
patient for TAVI. A safe distance rom the lower part of left main coronary artery to 
the aortic annular ring is 14mm an at least 10mm is the minimum recommended 
space. However, coronary occlusion may ensue even when these safety distances 
are preserved. This may happen because of the presence of redundant aortic leaflet 
that, after being apposed between the prosthetic valve and the aortic wall in fully 
opened position may reach e coronary ostium causing its occlusion. Similarly, a tight 
sino-tubular junction diameter may not fully accommodate the crashed leaflets of 
the native valve that may reach with its more distal segment the origin of the 
coronaries. A practical trick before deciding whether to implant a valve in doubtful 
cases is performing an aortic angiogram while the balloon for aortic valvuloplasty is 
fully inflated in the aortic root. Figure 26A shows a case of a widely patent left 
coronary artery during balloon inflation and a complete occlusion of the right 
coronary artery. In cases with no other therapeutic options, and with the developing 
of growing experience, TAVI in such cases can be afforded with reasonable safety. It 
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is absolutely recommended hawever, to place a long (300cm) 0.0014” coronary 
guide-wire along the coronary at risk of occlusion. The guide-wire alone can be 
introduced through the diagnostic femoral access using an 8 or 9F sheath and a 6F 
guiding catheter that is then removed [Figure 26B], leaving the wire alone as a rapid 
access to advance a coronary balloon in case of coronary occlusion to rapidly restore 
the flow in the artery. If further intervention is need a guiding catheter can be 
advanced through the wire to complete the job. Alternatively, both, the wire and a 
guiding catheter can be left in place using a different vascular access, preferable 
through the radial route.  
Procedure: an 89-year old female with medical history of hypertension, 
dyslipidemia, and severe AVS had several episodes of syncope in last 3 month. Six 
months before, she had been admitted to another hospital with an acute coronary 
syndrome that required emergent angioplasty of the right coronary artery with 
implantation of a stent at the right coronary artery ostium. TTE during 
hospitalization showed severe AVS (PG-70mmHg, MG-44mmHg, AVA-0.6cm2/m2, AA-
18mm) with moderate aortic and mitral regurgitation and a well preserved left 
ventricular function (LVEF=60%). TAVI screening with angio-CT showed good femoral 
artery diameters, but a rather low right coronary artery take-off (7-8mm). After 
implantation of a Prostar XL 10F closure device, balloon valvuloplasty with a 
20x40mm balloon was performed, and the aortography during balloon inflation 
demonstrated a totally occluded right coronary artery [Figure 26A]. Due to the ostial 
lesion, the stent, and the risk of coronary occlusion, a 300cm coronary angioplasty 
guide-wire was placed along the right coronary artery [Figure 26B]. The aortic 
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prosthesic valve was properly positioned under fluoroscopic and TEE monitoring 
without apparent coronary complication and normal ECG. The guide wire was 
removed and angiography showed normal flow in the coronary arteries [Figure 26C].  
Figure 26 Bailout guidewire in coronary artery 
 
A) aortography during balloon valvuloplasty showing occluded right coronary artery along 
with normal flow in left coronary artery; B) guide-wire in right coronary artery during device 
placement; C) aortography after  device deployment showing normal coronary flow 
Coronary artery occlusion is an infrequent but serious complication of TAVI 
[46,51,55,63-68].  Similar cases as the one described above are regularly performed 
in our center using protection wires when there is any suspicion of a possible acute 
coronary occlusion after valve deployment. This awareness prolongs the procedure 
by only a few minutes, but permits a rapid management of the massive ischemia 
caused by coronary occlusion that may rapidly evolve into irreversible 
haemodynamic impairment or arrhythmic storm in these old and fragile patients. 
100 
 
11.14 How to overcome renal faillure obstacle for TAVI? feasibilty and safety 
of TAVI without constrast medium. Is expert transesophageal 
echocardiography is alternative? 
 
Renal function is one of the most important predictors of long-term outcome of 
patients with cardiovascular disease [70]. Transcatheter interventions and contrast 
media administration can both exert deleterious effects on renal function and the 
risk is in direct relationship with the baseline renal function. Accordingto recent 
guidelines, general preventive measures must be applied as in any catheter-based 
intervention [71]. However, some additional precautions may help to avoid or 
reduce the risk of renal impairment in patients with diffuse atherosclerosis of the 
aorta needing contrast media administration to implant the trans-catheter valves 
[72-74]. Intense saline hydration during the procedure can be better managed in 
patients treated under general anaesthesia, since mechanical ventilation can 
facilitate the management of peri-operative volumes overload that, in patients with 
severe AVS, impaired left ventricular function, and often secondary mitral 
insufficiency, may otherwise ensue pulmonary edema of difficult management 
without the assistance of well monitorized mechanical ventilation. Of utmost 
importance remains however, the limited administration of contrast media. In cases 
of severe renal dysfunction, performing a successful TAVI without the use of contrast 
media may be an ideal goal, but this requires a great experience of the heart team. 
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TAVI without contrast media in severe renal failure                                                                                                                         
A 77 year-old female with a known history of severe AVS (AVA 0.6 cm2/ m2, PG 
45mmHg), severe coronary artery disease with previous stent implantation and a 
recent anterior myocardial infarction, diabetes, severe CKD-class IV (without 
dialysis), and liver failure as a consequence of profound cardiogenic shock was 
transported by the Emergency Service to our Intensive Care Unit. During 
transportation the Emergency Medical Services reverted several episodes of 
sustained ventricular tachycardia with DC shocks. On admission blood pressure was 
65/40mmHg with atrial fibrillation; LVEF was 14%, serum creatinine-4.7mg/dl, total 
plasma-bilirubin-44.3umol/L [N-(1-17)] and serum alkaline phosphatase-1900 U/L [N-
(5-40)]. 
Procedure: an emergency aortic balloon-valvuloplasty was performed through the 
left CFA with a 25mm balloon. The trans-valvular gradient was reduced from 33 to 
5mmHg, blood pressure raised immediately to 95/60mmHg. Subsequently, coronary 
angiography showed a patent left circumflex and right coronary artery and a 
thrombotic sub-occlusion of a previously implanted drug eluting stent in the mid left 
anterior descending artery with TIMI flow grade 1. Aortic-iliac angiography showed 
moderately tortuouse and calcified arteries with non significant stenosis. Coronary 
angioplasty was not performed as the amount of contrast media given was near to 
the 4mL/kg limit. Three days later although signs of renal and liver failure persisted, 
balloon angioplasty of left anterior descending artery was performed. During a 2-
week hospital stay, left ventricular function improved up to 40% and serum 
creatinine dropped to 1.9 mg/dl. Aortic gradient however increased from 5mmHg 
102 
 
after valvuloplasty to 20mmHg suggesting both a partial valve recoil and left 
ventricular function recovery. Due to the high operative risk (Euro SCORE 68%) she 
was disqualified for conventional aortic valve surgery and the patient accepted a 
TAVI attempt. 
The procedure was performed under general anesthesia through a surgically 
explored right femoral artery. A 12° cranial 10° left anterior oblique projection 
obtained by angiography at the time of the emergency valvuloplasty was selected to 
properly visualize the severely calcified aortic valve [Figure 27A]. A “stand by” pig-
tail catheter was placed in the ascending aorta (in case of need for contrast 
injection). A 23mm Edwards SAPIEN XT transcatheter valve was successfuly 
implanted under fluoroscopy control only, using the calcifications of the aortic 
annulus as landmarks [Figure 27B] and TEE imaging [Figure 27C]. Intraoperative TEE 
confirmed the good position and functioning of the prosthesis valve. The patient had 
a favorable clinical evolution and was discharged one month later.  
Figure 27 Severe renal failure 
 
A) Projection selected for prosthesis implantation; B) Fluoroscopic guided device deployment; 
C) TEE guided device deployment 
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The present case demonstrates the feasibility of guiding a trans-femoral TAVI with 
fluoroscopy and TEE without administration of contrast media, and may represent a 
step further on the possibilities offered by TAVI in patients with severe renal 
insufficiency. Due to the extraordinary setting of this procedure, the case has been 
published elsewhere [75]. 
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11.15 Safety and feasibilty of the Subclavian approach in the TAVI  
 
This vascular access may prove useful in some selected cases and when operators 
have developed high levels of expertise with TAVI [59,76]. 
We report as an example, the case of an 82-year old man with symptomatic AVS 
admitted for heart failure. He had two previous cardiac coronary bypass surgeries in 
1979 and 1999 and severe PVD, with multiple iliac-femoral artery stenosis including 
a previous stenting of the left external iliac artery and right SFA angioplasty in 2005, 
a totally occluded right internal carotid artery, and a previous left carotid artery 
endoartheriectomy. The right subclavian artery was deemed to be the only possible 
vascular access due to its acceptable diameter (6.2mm at angio CT scan) despite 
moderate tortuosity [Figure 28A], in a patient with a logistic EuroScore 59%. A trans-
succlavian implantation of 29mm CoreValve prosthesis was planned. 
Procedure: the procedure was performed in general anesthesia with surgical 
exploration of the right suclavian artery. An 18F introducer sheath was passed over 
an extra-stiff 0.035” wire [Figure 28B], and the 29mm CoreValve delivery system was 
successfully implanted under fluoroscopic control and rapid ventricular pacing 
[Figure 28C]. Intra-operative post implant TEE showed a properly placed and well 
functioning valve. The subclavian artery access site was closed surgically without 
complication and the patient was discharged uneventfully 7 days later.  
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Figure 28 Subclavian approach 
 
A) PreTAVI angiography of right subclavian artery; B) Fluoroscopic view showing introduction 
of sheath through right SCA; C) Insertion of device through right SCA 
 
The subclavian artery approach may be an option in patients with no other 
alternatives. Severe complications have been reported with the subclavian access as 
well [76], and therefore it should not be proposed as a routine alterative to the 
simpler femoral route; furthermore, no dedicated material is available to be used 
though the subclavian access and its use is recommended only after an extensive 
TAVI experience.  
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11.16 Step by step approach for a case of severe multi-level vascular disease  
waiting for TAVI                                                                                           
A 79-year old lady with medical history of hypertension, dyslipidemia, CKD class III 
with a known severe AVS was referred to our Laboratory for pre-operative 
catheterization. She was symptomatic for angina during daily activities, had a 
previous history of TIA, and was recently admitted for syncope. TTE confirmed the 
severe AVS (MG-55mmHg with preserved LVEF=65%). Angiograms revealed a severe 
left main stenosis at the ostium [Figure 29A] and severe bilateral internal carotid 
artery stenosis [Figure 29C]. 
After discussion within the Heart Team, the decision was made of treating the left 
main stenosis with a relatively simple angioplasty to avoid combined CABG and 
SAVR. Logistic EuroScore was 45%. 
Procedure: the coronary procedure was performed by the radial route with optimal 
result [Figure 29B]. One week after coronary angioplasty, the right internal carotid 
artery was treated with a 7x40mm self expandable meshed stent implanted after 
positioning an EPI EZ filterwire embolic protection device (Boston Scientific Corp., 
Natick, Massachusetts) [Figure 29D]. 
After these multi-level endovascular treatments, and considering the good quality of 
the aorto-iliac and femoral vessels, a staged TAVI was considered as a rapid and less 
invasive alternative to SVAR. Indeed, some days later a 26mm Edward- Sapien 
prosthesis was implanted under rapid pacing with a good immediate result [Figure 
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29E-F] confirmed by the intra-operative TEE. Post-operative course was uneventful 
and the patient was discharged one week later. 
Figure 29 complex TAVI candidate 
 
A) Severe left main stenosis (arrow); B) Angiography after left main stenting; C) Right and left 
internal carotid artery stenosis (arrows); D) Right internal carotid artery after stenting; E) 
Aortic prosthesis at aortic root level; F) Angiography after deployment of prosthesis 
Treatment of the elderly patient with multi-level vascular disease is complex and 
needs thorough evaluation by a multi-disciplinary team. This case shows the 
feasibility, safety, and reduced invasiveness of staged endovascular procedures that 
may be particularly appropriate in old and fragile patients with multi-level vascular 
disease and severe symptomatic AVS. 
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11.17 Safety and feasibilty of TAVI in the patient of AVS with associated 
severe mitral regurgitation, coronary artery disease, and heart failure 
 
Severe mitral regurgitation associated to AVS has been considered a contra-
indication for TAVI [52,65]. In particular, patients with impaired LVEF and severe 
mitral disease may not improve their long-term prognosis even after aortic valve 
replacement. However, mitral regurgitation itself does not pose technical difficulties 
to the TAVI, and releasing the left ventricle from the outflow obstruction caused by 
the AVS may result in a significant reduction of the mitral regurgitant volume with 
subsequent clinical improvement [77].   
This is the case of an 83-year old lady with a previous large anterior myocardial 
infarction and severe secondary mitral regurgitation that later developed severe 
AVS. She was admitted with refractory heart failure, in NYHA class IV despite 
continuous i.v. infusion of furosemide, and inotropes, with no clinical improvement 
after two months of hospitalization in the Geriatric Department. She was transferred 
to our Center for coronary angiogram and eventually balloon aortic valvuloplasty. 
Left ventriculography showed severe mitral valve regurgitation [Figure 30A]. LVEF 
was 23%, the mitral regurgitant volume was 60ml and the pulmonary artery systolic 
pressure was 56mmHg. 
Procedure: during a single catheterization suite the patient underwent coronary 
artery angioplasty of a co-dominant left circumflex; the left anterior descendent 
artery was chronically occluded. After angioplasty, aortic valve valvuloplasty was 
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performed with a 23mm balloon under rapid pacing. PG was reduced from 38mmHg 
to 10mmHg and the subsequent clinical evolution was impressive, with rapid 
weaning from inotropes and i.v. diuretics and resolution of the chronic bilateral 
pleural effusions in about two weeks [Figure 30B-30C]. She had rapid clinical 
improvement and returned to walk after several months of bed resting, and was 
discharged. After two months she had returned to her previous activities. The mitral 
regurgitant volume was reduced to 48ml, and the EF increased to 36% after aortic 
valvuloplasty. The case was considered for TAVI and the procedure was performed 
successfully with the implantation of 23mm Edwards-Sapien prosthesis through the 
femoral route by using a totally percutaneous approach and on local anesthesia. At 3 
months follow up the patient was in functional class I, EF was 40%, pulmonary artery 
pressure was 28mmHg and mitral regurgitation was further reduced to 38ml in the 
left atrium. After 2 years of follow-up the patient is still doing well. 
Figure 30 TAVI in severe mitral regurgitation 
 
30A) Ventriculography showing severe regurgitation in left atrium; 30B) chest X-ray showing 
bilateral pleural effusion before balloon valvuloplasty; 30C)chest X-ray showing resolution of 
pleural effusion 2 weeks after balloon valvuloplasty 
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This is a case of end-stage heart failure due to major cardiac contra-indications to 
TAVI and extremely fragile clinical conditions: severe mitral regurgitation and severe 
left ventricular impairment, associated to severe coronary artery disease. In such a 
case, percutaneous myocardial revascularization and aortic balloon valvuloplasty 
may serve as an effective atempt to improve the general clinical conditions and offer 
a bridge to a definitive treatment.   
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12. Discussion 
 
TAVI is now a viable option in the treatment of inoperable/high-risk severe 
symptomatic AS. It has been shown to reduce mortality compared with a 
conservative strategy among patients deemed inoperable [64-68] and resulted non 
inferior to conventional AVR in high surgical risk patients [65]. 
Present series of patients, we have analyzed the global clinical and 
echocardiographic outcome of TAVI considering both immediate and long-term 
outcome. This monocentric registry takes into account a wide population including 
patients with native AS, combined AS plus regurgitation and bioprosthesis 
dysfunction, and treated with both commercially available devices, using all the 
approaches currently adopted: TF, TA and subclavian. 
The main finding of our analysis is that TAVI is a safe and effective procedure leading 
to early clinical and hemodynamic improvement and persisting benefits over time. 
Periprocedural mortality and procedural complications are extremely low and long 
term outcome seems related more often to extracardiac comorbidities of this kind of 
patients. 
In the present series almost all patients are elderly with mean age of 81.9 + 6.3 year 
along with several co-morbid conditions like hypertension, diabetes, coronary artery 
disease and more. In spite all these procedural success was 93.1 %. Prosthesis was 
hemodynamicaly well functioning even on long term follow up. However, complexity 
of the patient at presentation affects the short term and long term outcome. As per 
our opinion special care should be given to achieve success. Balloon valvuloplasty, 
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bridge to TAVI, is reasonable option for critically ill patients which is followed by step 
TAVI. In special category of patients which are presented with multiple vascular 
pathologies, as we have mentioned in complication section, may be treated by 
sequential manner. 
As per prosthesis concerned, Edward-Sapien is most commonly used at our centre 
which has high success rate. Core-Valve was used in specific aortic valve pathology 
like severe aortic insufficiency, dysfunctioning aortic valve prosthesis, large annulus 
and difficult vascular access for Edward delivery system. Conduction difficulty after 
aortic valve replacement is well known from era of surgical replacement due to 
anatomically close relation. Recetly published studies showed increase incidence of 
conduction problem, mostly with CoreValve prosthesis [78-81]. In our small series of 
patients conduction problem was found in 10(13.89%). Among them 5 patients 
comes to normal rhythm with 24 hours, however, 5 needed permanent pacemaker 
implantation. Incidence of permanent pacemaker implantation was high with 
CoreValve (23.1% of all CoreValve), however, in Edward-sapine was only 3.4%. 
Amount of constrast, ventilation time and procedure time varies with every patient. 
However as per our experience, ventilation time and procedure time was longer with 
trans-apical TAVI than transfemoral TAVI. On table extubation and early 
immobilisation are advantages of transfemoral approach. 
Complication immediately after procedure was not uncommon found in 34 (47.2%) 
of patients. Detailed of these complications and their management was mentioned 
in special title below. As in most TAVI registries vascular complications were most 
common; among them 14 (41.2%) which was treated with our experience in 
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peripheral artery interventions [63-67]. Moderate to severe aortic prosthesic 
regurgitation attributed to 7 (20.6%) which was managed with post-dilatation of 
prosthesis with valvuloplasty balloon of appropriate size or implantation of another 
prosthesis. Interesting finding in this series was presence of thrombus like 
echographic shadow around the implanted prosthesis 4(11.8%) which was treated 
with control echocardiography and heparin infusion. We think that may be disrupted 
native aortic valve leaflet gives these type of images. However, we are afraid that 
whether this structure may acts as nidus for the future thrombus formation which 
may gives rise to cerebral stroke which we found in 2(50%) of these patients. 
Thirty days clinical and hemodynamic function of prosthesis has promising results. 
Prosthesis was functioning properly with significant increase in aortic valve area 
(P<0.001), decrease in peak gradient (P<0.0001), mean gradient (P<0.0001) along 
with trivial-mild degree of periprosthesis regurgitation. All cause mortality was 
relatively low 3(4.2%) considering high risk profile of patients. Mortality was found 
to be higher in patients undergoing trans-apical approach. Complexity of 
intervention and high operative risk was reasonable explanation.  Incidence of 
cerebral stroke events was comparably low 3(4.2) as in other studies [dggd]. Vascular 
complications like puncture site hematoma was even common at 30 days follow up 
(20.8%). 
Long term follow up was performed up to maximum of 2.9 year in all 69 patients 
remained alive at 30 days. All cause mortality was relatively low 11(15.9%) 
considering high co-morbidities. Mortality was with the non-cardiac reasons in 
7(63.64%) of all died, only 4(36.36%) died with cardiac causes. Cardiac mortality was 
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earlier with mean duration of 190 + 304 days as compare to non-cardiac death at 
271 + 278 days. Single patient on heart transplant list with Heart Mate II was treated 
for aortic valve insufficiency with Core-Valve was transplanted after 6 months. 
In the 57 patient remained alive at long term follow up most of them are without 
symptom for aortic valve stenosis. Clinical status assessed with NYHA class which 
was improved in most of patients as compared to baseline. Only 33.4% of patients 
were in class III/Iv functional NYHA class as compare to 59.8% at baseline. A frality 
scale was improved and most of them are autonomous with their daily activities. 
Incidence of rehospitalisation was 18 (31.6%) in this series of patients mostly for non 
cardiac reason 14 (77.8%) than cardiac 4 (22.2%). Incidence of composite outcome of 
mortality and rehospitalisation was higher up to 32(44.4%). Bleeding complications 
like was found in 12 (21%). Incidence of cerebral stroke was maintained as short 
term follow up 3 (5.3%) even in long term. 
In almost all patient prosthesis was functioning properly with maintaining significant 
increase in aortic valve area, decreasing peak gradient, and mean gradient as found 
in short term follow up. Re-intervention for aortic valve prosthesis was not needed in 
single patient. We found marked decrease in grade of aortic prosthesis regurgitation 
as compare to 30 days follow up. Moreover, left ventricular systolic function was 
improved on long term follow up. Only 11(19.3%) of patients has poor left 
ventricular function (<50%) as compare to 29(40%) before TAVI. Most of patients 
with poor left ventricular function were died. On multivariate logistic analysis we 
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found that poor left ventricular function (EF<50%) is strong predictor of short term 
and long term mortality (P<0.01). 
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13. special cases, complications and their management 
 
13.1 Challenges from the femoral vascular access 
TAVI can be achieved by several accesses, such as the trans-femoral, trans-
apical, trans-aortic, sub-clavian and trans-axillary [46,52]. Among these, the trans-
femoral is the most preferable route as it is the less invasive. We believe that during 
the initial phase of a “TAVI learning curve” the femoral access should be managed 
surgically so that interventional cardiologists could concerte in learning tips and 
tricks of the valve implantation exclusively, without adding complexity to the 
procedure related to the percutaneous management of the vascular access with  the 
Prostar XL closure device. It is obvious that such recommendation does not apply to 
operators that are already proficient with the use of this closing device. 
Before selectingthe femoral approach, the operator should well analyse 
diameter, tortuosity, and calcification of the common femoral artery (CFA), external, 
and common iliac arteries [46,52]. Furthermore, the exact location of the calcium 
with respect to the anterior wall of the CFA is crucial during implantation of a closure 
device. The operator must know the vascular situation of the inferior limbs, in 
particular patency of the superficial femoral artery (SFA), or collateral circulation, 
and the quality of the infra-renal aortic wall.  
To this aim, both, computerized tomography (CT) scan and contrast 
angiography are essential pre-TAVI examinations. CT scan offers accurate 
information about the vessels anatomy and disposition, the severity and localisation 
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of calcifications, it offers reliable measurements in non-calcified tracts, but tends to 
under-estimate vessel diameter in calcified segments [46,52] Contrast angiography 
as a screening for potential TAVI candidates should be ideally performed by the 
radial access to avoid complications at the femoral puncture site during the 
diagnostic examination. Angiography adds an important perception to the 
estimations of the vessels diameter, and being a dynamic imaging, shows the degree 
of rigidity or flexibility of the aortic-iliac-femoral axe by analysing its systolic-diastolic 
excursions. The more flexible the vascular axe, the more likely it will accommodate 
the large introducer sheath despite relatively small diameters, or marked tortuosity. 
Apparently challenging tortuosity as shown in [Figure 31A-B], can be easily afforded 
when the vessel is elastic and not severely calcified. Also small arteries (less than 
5.5mm) can safely accommodate the 18 or 19F sheath when are not calcified [Figure 
31C-D]. However, much caution is required in these cases with delicate 
advancement of the dilators and introducer, avoiding energic pushing that may 
cause arterial rupture. Angiography provides also valuable information about the run 
off of the contrast media along the SFA and the dynamic of collateral circulations 
when important vessels are occluded. Knowledge of the SFA angiographic anatomy is 
essential for the positioning of a contralateral safety guide-wire, as discussed later in 
this article.  Last, accurate selection of the exact point for the puncture of the CFA 
(well above the bifurcation of the SFA and the profunda) is clue, avoiding sites with 
calcium in the anterior arterial wall where the introducer and then the Prostar 
needles will be implanted [Figure 31E-F]. 
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Figure 31 vessel anatomy 
 
31A) Angiography showing bilateral tortuous ilio-femoral arteries; 31B) CT Scan showing 
bilateral tortuous ilio-femoral arteries. Despite marked tortuosity a 21 F introducer sheath 
was advanced into the right iliac axe without dificulties; 31C) CT Scan showing relatively 
small iliac arteries without calcification (arrows). The maximum diameter measured in the 
comon iliac was 5.5mm. However, a 21 F introducer sheath was advanced without 
complications; 31D) CT Scan sagittal section showing relatively small iliac arteries without 
calcification (arrow); 31E) CT Scan reconstruction showed severe calcification on left CFA 
with a small area withou calcification (arrow); 31F) The fluoroscopic view shows the accurate 
position of the puncture site taking account of the CT Scan in the same patient shown in 
figure 1E. 
 
The most challenging situations for the femoral vascular access are dictated by the 
presence of severely calcified stenosis in the iliac-femoral axe. These may be a 
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contra-indication to the femoral route, but with the continuos improvement in 
delivery systems and skills in peripheral artery interventions, the success without 
serious complications can be achieved in most cases as shown in the following 
examples.  
13.2 “Tunnelling” of femoral arteries 
An 85-year old man with severe aortic stenosis was repeatedly admitted in hospital 
with syncope and heart failure. He had previous cardiac bypass surgery and a severe 
impairment of the LV function and chronic atrial fibrillation, hypertension, diabetes 
mellitus, moderate chronic kidney disease (CKD) (calculated clearance 35ml/h/m2) 
and severe PVD. The logistic Euroscore was 55%. Pre-TAVI transthoracic 
echocardiography (TTE) showed aortic annulus 23mm, EF=27%, pulmonary artery 
pressure (PAP)-65mmHg and CT scan and angiography showed adequate iliac-
femoral diameters with multiple calcified plaques. A 26mm Edward prosthesis was 
scheduled by trans-femoral route. 
Procedure: Anaorto femoral angiography showed apparently suitable vasculature for 
femoral access (left and right common iliac artery diameter was 9.5mm and 10mm 
respectively; CFA diameter was 6mm and 6.5mm on left and right side respectively) 
[Figure 32A].The procedure was performed under general anaesthesia and with 
surgical exploration of right CFA. Due to the extensive calcifications, and the extreme 
vascular rigidity, it was not possible to introduce the 14F dilator in the era of 
retroflex 22F sheath. The right femoral artery was dilated using 8mm and 10mm 
balloons over the extra-stiff wire [Figure 32B] but without success in introducing the 
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dilator. After several dilations, there was a clear evidence of bleeding due to vascular 
rupture, therefore, despite the fact that implantation of stents before passing the 
large 22F sheath may cause stent dislodgement and embolization in aorta, two self-
expandable covered stents of 10mm each were rapidly implanted through the same 
extra-stiff wire to control bleeding [Figure 32C]. Additional high-pressure balloon 
dilatations were needed to allow the 22F sheath pass into the common iliac artery. A 
26mm Edward-Sapien prosthesis was implanted after balloon valvuloplasty without 
difficulties. The vascular access site was repaired surgically with the need of a short 
vascular Teflon prosthesis to reconstruct the anterior wall of the CFA. Post-operative 
course was uneventful.  
Figure 32 Femoral artery tunnelling  
 
A) AngioCT showing measurement of right iliac-femoral arteries; B) Fluroscopic view showing 
balloon dilatation of ilic-femoral axis; C)Fluroscopic view showing stented iliac-femoral axis 
(segment between asterisks) and contrast media that exits the vessel lumen due to a 
perforation (arrow) 
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Although the diameter of ilio-femoral axis by angiography and CTscan were 
adequate, the diffuse atherosclerotic disease, and the use of a “first generation” 
introducer sheath created a serious obstacle to the TAVI procedure. Tunnelling the 
vascular axe with aggressive balloon angioplasty and implanting self-expanding 
covered stents allowed both, to solve the bleeding complication, and to implant the 
prosthesic valve successfully. However, implanting stents before placing the 
introducing sheath is not recommended, and should be reserved for emergency to 
avoid life threatening bleeding. This technique is an option when a surgical cut down 
of the artery is used as vascular access, but as described later in this article, a 
different technique is recommended if a totally percutaneous approach is selected. 
13.3 Sessile thrombus in aortic root after transapical aortic valve implantation 
The occurrence of cerebrovascular events has a major concern from the very 
beginning of the transcatheter aortic valve implantation (TAVI) era. Transapical TAVI 
was first reported as an alternative to the transfemoral in 2006 [82]. Although more 
invasive, it has the potential to avoid the use of large catheters through the 
atherosclerotic iliofemoral system, aortic arch and ascending aorta, thus contributing 
to reduce cerebrovascular events [83].  
A 72 year old male with severe aortic stenosis (peak gradient- 80mmHg; mean 
gradient- 55mmHg; aortic valve area-0.50 cm2/m2, arotic annulus-26mm), 
hypertension, insulin-dependent diabetes, and chronic renal failure was admitted 
with syncope and cardiogenic shock. He had previously undergone bilateral carotid 
endartectomy and CABG. PreTAVI screening confirmed normally functioning bypass-
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grafts, non significant carotid arteries. Transapical TAVI with 29mm Edward Sapien 
prosthesis was therefore proposed to the patient by the heart team. 
 Transapical TAVI was performed at our centre under general anesthesia through a 
left lateral minithoracotomy [84].  The activated coagulation time was maintained > 
250 sec with heparin. Transesophageal echocardiography immediately after balloon 
valvuloplasty showed moderate aortic valve insufficiency [Figure 33A]. A 29mm 
Edward Sapien XT ( Edwards Lifesciences, Irvine, CA, USA)  was then successfully 
deployed by the Ascendra delivery system [Figure 33B]. Post-deployment 
aortography showed trivial prosthetic regurgitation whereas TEE showed a properly 
placed and functioning device (MG-8mmHg; AVA-2.4mm2) with only mild 
periprosthetic leak, but a sessile thrombus like structure (2X4 mm size) was attached 
along the non coronary leaflet [Figure 33C].  
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Figure 33 sessile thrombus around implanted prosthesis 
 
A) TEE showing aortic regurgitation after balloon valvuloplasty; B) Fluoroscopy showing 
deployment of 29mm Edward Sapien XT prosthesis; C) TEE showing sessile thrombotic mass 
along non coronary leaflet; D) TEE showing persistent thrombus around prosthesis 
 
Continuous TEE monitoring performed until closure of minithoracotomy incision. 
Thrombus was still present [Figure 4D]. Neurological examination at 1,6,12,24 and 
48 hours after procedure showed normal sensory and motor function. Cranial CT 
Scan before discharge showed small multiple ischemic focuses in left cerebral 
hemisphere without neurological abnormality. Follow up visit after 2 month showed 
normally functioning valve prosthesis without any neurological problem. 
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The occurrence of cerebral embolism and stroke are most worrisome complications 
which associated with TAVI. The 30-day stroke rate was approximately 3.5% (1.2%-
6.7%) in multicentre registries and the PARTNER trial. Stroke seems to be affected by 
TAVI approach, TF vs TA; Canadian study (3% vs 1.7%); France registry (4.2 % vs 
2.8%); SOURCE registry (2.4% vs 7.19) [51,63-68].  
We here reported a case of tranapical TAVI, as per our knowledge first reported 
which presented with sessile, floating thrombus in aortic root immediately after 
prosthesis implant which may act as “nidus” for further development of 
thromboembolic phenomena in postoperative TAVI. The mechanism of stroke during 
TAVI needs to study before wide use of cerebral embolic protection device. 
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14. Conclusion 
 
TAVI represents a less invasive strategy than SVAR. It offers an extraordinary option 
for symptomatic patients with severe AVS who are either, no candidates to SAVR, or 
present an unacceptable surgical risk. The rapid development of the technique is 
making of TAVI a “routine” practice in high-volume centres. By now, all efforts 
should be made to improve procedural success by reducing peri-procedural 
complications. Along with other important factors, patient’s selection is clue. 
Procedure planning, using proper approach, interventional materials, and application 
of coronary, structural and peripheral interventional skills, in the context of an 
accurate clinical management will certainly help to obtain optimal results. 
Transapical and TF approaches are the most frequent established techniques to 
perform a TAVI, with others new approaches such as the transubclavian and the 
transaortic ones leading to further expansion of current eligibility criteria. 
Nonetheless, a fundamental key for the success of a TAVI program remains the 
effective and respectful cooperation between cardiologists and surgeons, and the 
observation of the available evidence-based indications. TAVI procedures beyond 
this context, imposes thoughtful discussion within the Heart Team and a great deal 
of experience. 
Recently the indications to TAVI are extending also to particular settings of patients. 
To this regard, one very promising indication is the treatment of severe aortic valve 
regurgitation in Heart Mate II patient. In these patients valve prosthesis may be act 
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as bridge to heart transplatation. Second important application is treatment of 
bioprosthesis dysfunction by the so called valvein-valve technique, allowing to avoid 
a second sternotomy and giving overwhelming results. 
The main concerns about TAVI still regard the risk of embolic complications, 
conduction defect, periprosthetic leakage and vascular complications. There is no 
doubt that with technology development and learning experience these 
complications rates are much lower nowadays and will likely continue to drop. 
Cost effectiveness of this procedure is currently a topic of criticism. Moreover, 
recently transarterial AVR has arguably become the standard of care for patients for 
whom surgical risk is prohibitive and an increasingly reasonable alternative for 
selected operable patients in whom the high-risk of either mortality or of morbidity 
is “high.” Broader application will require further refinement as well as more 
rigorous and longer follow-up. It is possible that, with time, TAVR will become a 
preferred option for a much broader group of patients. A major concern may well be 
the following: When are patients too ill, frail, or old to gain significant benefit in 
terms of duration or quality of life? 
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